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The Functional Analysis of a Major Tyrosine Phosphorylation Site on Actin
Amelie Simone Cordelia Albrecht, B. Sc.

Advisory Professor: Xuetong Shen, Ph.D.

Actin is an abundant and evolutionarily conserved protein and a key component of the
cytoskeleton. Post-translational modifications of actin are emerging as an important
mechanism for regulating actin functions, and may form an ‘Actin Code’. In this work, I
investigate the role of actin phosphorylation at tyrosine 53 (pY53), one of the most
frequently detected actin PTMs, through identifying interaction partners, or ‘readers’, for this
modification. Using an SH2 (Src Homology 2) protein domain array, we identify N-terminal
SH2 domains of p85, regulatory subunits of Phosphatidylinositol 3-kinase (PI3K), and VAV2,
a Rho GTPase guanine nucleotide exchange factor, as phosphorylation-dependent binding
partners of an actin pY53 peptide. Through biochemical and structural biology approaches, I
define the interaction mechanism of the actin pY53 peptide with p85α, p85β and VAV2. My
work provides evidence for an interaction mechanism of the actin pY53 peptide to the p85
N-terminal SH2 domains that is partially distinct from the canonical mechanism as it lacks
the common binding motif for this domain. Moreover, I present the first high-resolution
crystal structure of the p85β N-terminal SH2 domain bound to a peptide ligand.
I also performed functional analysis of the possible roles of the actin pY53 modification.
To do so, I generated a human cell line with β-actin Y53F mutation to abolish
phosphorylation of this residue, using CRISPR/Cas9-based gene editing. I find that this cell
line exhibits slightly higher levels of AKT phosphorylation, as well as an altered gene and
protein expression profile that includes components of the PI3K pathway.
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Taken together, my findings suggest that actin tyrosine 53 phosphorylation may play a
role in cell signaling, possibly through the phosphorylation-dependent interactions with SH2
domains of p85 and/or VAV2 proteins, and highlight a largely unexplored, and potentially
highly important area of actin biology through its post-translational modifications and their
‘reader’ proteins.
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Chapter I: INTRODUCTION
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Part One: Actin is a versatile protein involved in multiple cellular processes

Cellular roles of actin
Actin is one of the most abundant and evolutionarily conserved proteins and is present in
virtually all eukaryotes (Pollard and Cooper 2009). Its ability to polymerize and form dynamic
filaments makes actin a key element of the cytoskeleton that enables cell movement,
division and intracellular vesicle transport (Pollard and Cooper 2009). Together with myosin,
actin generates the mechanical forces necessary for movement and muscle contraction; this
principle was first established by Szent-Györgyi and Straub in the 1940s, who purified
‘actomyosin’ from muscle and discovered its ATP-dependent contractility (Bugyi and
Kellermayer 2020). Since then, a large body of research has focused on determining actin
functions in a large number of cellular processes (Pollard 2016; Pollard and Cooper 2009).
In the cell, actin exists in the form of monomeric G-actin and filamentous F-actin and
actin filaments are dynamically assembled and disassembled with the help of actin-binding
proteins (ABPs) as well as actin ATP hydrolysis, in a process known as ‘treadmilling’
(Figure 1) (Artman et al. 2014).

Figure 1. Actin can polymerize from monomeric G-actin to filamentous F-actin. Actin
monomers bound to ATP are preferentially added to the barbed (+) end. ATP hydrolysis
occurs and ADP-bound monomers depolymerize at the pointed (-) end of the actin filament.
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Filament growth can push the cell membrane forward and is the driving force behind cell
motility (Pollard and Borisy 2003). Moreover, during cell division, actin is part of the
contractile ring, that, in concerted action with myosin and other proteins, helps to separate
the two emerging daughter cells (Heng and Koh 2010). In a similar way, actin is involved in
endocytosis and forms a dense network at the plasma membrane that aids in membrane
deformation, vesicle maturation as well as vesicle transport (Schuh 2011; Mooren, Galletta,
and Cooper 2012).

While the cytoplasmic functions of actin are well-established, the existence of nuclear
actin had long been questioned due to the difficulty of detecting actin filaments with
conventional methods. However, it is now established that actin is present in the nucleus
and important for many nuclear processes (Serebryannyy and de Lanerolle 2020).
Monomeric actin and actin-related proteins are conserved subunits of ATP-dependent
chromatin modifying complexes such as INO80, SWR1/SRCAP, BAF and TIP60 and in
these complexes, actin is required for their functions in chromatin organization, recruitment
to nucleosomes, overall complex stability, and DNA damage repair (Kapoor et al. 2013;
Kapoor and Shen 2014). In addition to chromatin modifying complexes, actin is also
associated with basal transcription machinery and involved in transcription regulation: it
interacts with all three RNA polymerase complexes and several transcription factors, as well
as nascent transcripts through heterogenous nuclear ribonucleoproteins (hnRNPs) (Miralles
and Visa 2006). More recently, actin filaments and actin-binding proteins have been shown
to play a role in DNA damage repair; together with other proteins, they help to move
damaged loci to the nuclear periphery to promote repair (Caridi et al. 2018; Schrank et al.
2018).
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Mechanisms of actin regulation
Precise spatio-temporal regulation of the diverse range of actin functions is highly
important for the cell and is tightly regulated by several mechanisms: these include
controlling the overall amount and localization of actin through transcriptional and
translational regulation, the direct regulation by actin-binding proteins (ABPs) as well as
post-translational modifications (Kashina 2020).
Actins are a family of proteins encoded by six genes in humans that are expressed in a
spatially and temporally controlled manner: Actin isoform expression is partially tissuespecific, with some isoforms being more abundant in smooth or skeletal muscle tissue (αskeletal, α-smooth muscle, γ-smooth muscle as well as cardiac muscle actin), and others
being more prevalent in non-muscle tissues (β-cytoplasmic, γ-cytoplasmic actin) (Kashina
2020; Tondeleir et al. 2009). However, it is becoming more apparent that most cell types
contain more than one actin isoform, albeit in different relative amounts (Kashina 2020).
Interestingly, differences in protein levels appear to not be primarily due to differential
expression of transcripts, but rather appear to be mediated by post-transcriptional
mechanisms (Kashina 2020). While all actin isoforms are highly conserved and differ only in
a few amino acids, mostly at the N-terminus of the protein, they do fulfill specialized
functions and cannot completely compensate for each other’s absence (Cheever and
Ervasti 2013; Cheever, Li, and Ervasti 2012; Kashina 2020). Notably, only knockout of βactin is early embryonically lethal; it has been proposed that one of the reasons other actin
isoforms cannot compensate for the absence of β-actin is due to differences nucleic acid
level, possibly because of different mRNA translation rates (Vedula et al. 2017; Patrinostro
et al. 2017; Patrinostro et al. 2018). Despite a high degree of similarity between the actin
isoforms, their existence, evolutionary conservation and differential transcriptional and
translational regulation strongly indicate a need for tight control of actin localization and
abundance (Kashina 2020).
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Actin functions are also controlled by interactions with numerous actin-binding proteins
(ABPs) (Pollard 2016), which is considered to be one of the main paradigms of actin
regulation. ABPs have diverse roles, such as to promote nucleation to form new filaments
(for example formins, WASP and the ARP2/3 complex), regulate polymerization (for
example profilin), depolymerization (for example cofilin and gelsolin) and bundling of actin
filaments (for example α-actinin, fascin and fimbrin) (Pollard 2016; dos Remedios et al.
2003). Other ABPs use their actin-binding capability to regulate endocytosis, plasma
membrane association as well as cell-cell and extracellular matrix junctions, and, in addition,
proteins such as myosins, calponin and tropomyosin work together with actin to generate
force and regulate motor functions that are essential for muscle contraction and cell motility
(dos Remedios et al. 2003).

Actin post-translational modifications
Post-translational modifications (PTMs) are events that occur after protein translation
and encompass a very diverse spectrum of modifications, including covalent attachment of
functional groups, such as methylation, or even small proteins like ubiquitin, but can also
refer to targeted proteolytic processing of proteins (Wang, Peterson, and Loring 2014).
These mechanisms can significantly diversify the proteome as they generate proteoforms
with distinct functions or activation states, compared to the unmodified proteins, and can
also occur in tandem (Aebersold and Mann 2016; Lothrop, Torres, and Fuchs 2013). More
recently, advances in mass spectrometry have shown that PTMs, and especially
phosphorylation events, are surprisingly ubiquitous and occur on three quarters of all
proteins, and on over 50,000 unique sites in some cell types (Aebersold and Mann 2016).
Yet, for the majority of these phosphorylation sites, as well as other types of PTMs, their
function and mechanisms of regulation are unknown (Aebersold and Mann 2016); this
makes PTM studies a large and very important area of future investigation in biology.
5

The functions of actin have been studied for a long time and many of the proteins
involved in actin regulation are well-known (Pollard 2016). Actin post-translational
modifications have been occasionally identified and studied since the 1970s, however, only
more recent advances in mass spectrometry have enabled more comprehensive analyses
of the extent and diverse composition of actin PTMs (Terman and Kashina 2013). Functional
analysis of actin PTMs is still a small, yet rapidly expanding field (Kashina 2020; Terman
and Kashina 2013; Varland, Vandekerckhove, and Drazic 2019).

Actin phosphorylation
Actin phosphorylation was one of the earliest actin PTMs to be identified, and while early
studies often did not pinpoint the phosphorylated residue or even the type of modified amino
acid, they demonstrated an impact of phosphorylation on actin dynamics. For example, actin
from skeletal and smooth muscle can be phosphorylated by a cAMP-dependent kinase in
vitro, which reduces polymerization and mostly occurs on G-actin (Pratje and Heilmeyer
1972; Walsh, Hinkins, and Hartshorne 1981). This phosphorylation occurs on serine
residues and the authors suggest that S199 or S338 may be good substrates based on their
surrounding sequence (Walsh, Hinkins, and Hartshorne 1981). Interestingly,
phosphorylation of S199 of actin was later identified by large-scale phospho-proteomic
studies (Mertins et al. 2016; Sharma et al. 2014) and in kidney cells (Akimoto et al. 2019).
cAMP-dependent serine phosphorylation of actin also occurs in rat lungs and increases
dramatically in post-natal and adult lungs compared to fetal tissue, suggesting that it may be
developmentally regulated (Whitsett et al. 1985). Interestingly, actin is also phosphorylated
on both serine and threonine residues by PKC, but on different residues than by a cAMPdependent kinase (Ohta et al. 1987). PKC-catalyzed phosphorylation increases actin
polymerization while phosphorylation by a cAMP-dependent kinase does not show the same
6

effect (Ohta et al. 1987). Moreover, actin may be a target of EGF-dependent
serine/threonine kinases as it has been shown to coprecipitate with EGFR, but not be
phosphorylated by it directly (on tyrosine residues) (van Delft et al. 1995; Ohta et al. 1987),
suggesting that actin may be a substrate for kinases downstream of EGFR. In line with this,
the serine/threonine kinase PAK1 phosphorylates actin on serine residues and interacts with
it in a signaling pathway activation-dependent manner (Papakonstanti and Stournaras
2002). As phosphorylation can affect cytoskeletal dynamics, inhibition of serine/threonine
phosphatases, for example by Calyculin A, disrupts actin cytoskeletal structure (Gu et al.
2003). Lastly, actin has also been shown to be a direct substrate of the serine/threonine
kinase AKT and interacts with it directly in MCF-7 cells upon stimulation with FGF-2
(Vandermoere et al. 2007). Taken together, these studies indicate distinct roles for serine
and threonine phosphorylation of actin in different tissue types and by different kinases,
potentially functioning to finetune actin polymerization dynamics in a context-dependent
manner.

The first direct evidence for tyrosine phosphorylation of actin was found in the 1980s,
when it was demonstrated that actin is phosphorylated in vitro by purified plasma
membranes and is stimulated by both insulin and vanadate (a tyrosine phosphatase
inhibitor) (Machicao, Urumow, and Wieland 1983), indicating that it may be dependent on an
insulin-dependent tyrosine kinase. Previously, actin phosphorylation by purified plasma
membranes from rat livers had been shown to prevent the inactivation of DNase I by actin
and reduce polymerization (Grazi et al. 1980; Grazi and Magri 1979). However, it remained
unclear whether this effect is caused by serine/threonine or tyrosine phosphorylation.
The organism in which actin tyrosine phosphorylation has been studied in most detail is
the amoeba Dictyostelium discoideum. This organism has a particular life cycle that exhibits
both unicellular and multicellular features: while unicellular in nutrient-rich conditions, the
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cells migrate when starved of nutrients and go from vegetative growth into aggregation with
other cells to ultimately form a so-called fruiting body that contains spores that can be
released and restart the developmental cycle as soon as environmental conditions improve
(Annesley and Fisher 2009).
Actin tyrosine phosphorylation in D. discoideum is highly abundant and increased upon
treatment with the phosphatase inhibitor phenylarsine oxide (PAO) or when starved
amoebae are reintroduced to nutrient-containing medium (Schweiger et al. 1992; Howard,
Sefton, and Firtel 1993). Moreover, actin tyrosine phosphorylation correlates temporally with
changes in cell shape, is increased upon depletion of PTP1 phosphatase, and reduced upon
PTP1 overexpression (Howard, Sefton, and Firtel 1993), indicating that it is actively
regulated in response to environmental stimuli. Furthermore, actin phosphorylation in this
organism increases when the cells are exposed to stress, such as heat shock and cadmium
chloride (Liu et al. 2006; Jungbluth et al. 1995). Interestingly, actin tyrosine phosphorylation
also becomes more abundant during spore maturation and correlates with spore survival
(Kishi et al. 1998; Gauthier et al. 1997), suggesting that at least in D. discoideum, actin
tyrosine phosphorylation may be an important mechanism involved in development and
survival.
Work from the Korn group further established that phosphorylation of the Y53 residue in
D. discoideum is functionally relevant: by purifying phosphorylated actin, which can
constitute up to 50 % of total actin in this organism, and comparing it to unphosphorylated
actin, they demonstrated that pure Y53 phosphorylated actin does not inactivate DNase I
efficiently and reduces polymerization (Liu et al. 2006). The effect on polymerization is
caused by inhibiting nucleation and elongation from the pointed end of filaments, reducing
elongation from the barbed end as well as slower ATP hydrolysis (Liu et al. 2006). However,
pY53 and unphosphorylated actin co-polymerize in vitro and colocalize in cells (Liu et al.
2006). This suggests that when only a smaller fraction of actin is phosphorylated, which is
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likely the case under normal growth conditions, actin phosphorylation would not entirely
disrupt the cytoskeleton, but rather may serve as a mechanism to finetune its dynamics, as
was suggested in later work as well (Bertling et al. 2016; Bertling and Hotulainen 2017). The
effect on actin polymerization may be caused by stabilizing the structure of the D-loop of
actin: these residues (amino acids 39 - 51) of actin are normally a very flexible part of the
actin molecule and are often disordered in crystal structures (Dominguez and Holmes 2011).
However, when actin is phosphorylated on pY53 (in a structure bound to the actin-binding
protein gelsolin), the D-loop is stabilized by hydrogen bonds to the phosphorylated tyrosine
(Baek et al. 2008). Given that the D-loop is important for actin polymerization, its
stabilization by pY53 may explain the lower polymerization rates (Baek et al. 2008).

Actin tyrosine phosphorylation has also been studied in other organisms. For example,
in the contact-sensitive plant Mimosa pudica L., actin phosphorylation levels are high and
rapidly decrease when the plant is touched, indicating that actin phosphorylation could be a
mechanism to help plants react to environmental stimuli and rapidly reorganize their
cytoskeleton (Kameyama et al. 2000; Kanzawa et al. 2006).
Actin phosphorylation is also involved in host-pathogen interactions: in ticks infected with
Anaplasma phagocytophilum, altering host cell physiology, such as tyrosine phosphorylation
and the actin cytoskeleton, helps the bacteria to survive inside the host cells (Sultana et al.
2010). Interestingly, actin becomes phosphorylated in infected tick cells in a PI3K- and
PAK1-dependent manner, which results in a higher G- to F-actin ratio; however, the
identified phosphorylation site in tick actin (Sultana et al. 2010) corresponds to Y218 in
human β-actin. Of note, actin Y218 phosphorylation occurs in human B cells and is
regulated by SHP-1 phosphatase to modulate actin depolymerization after BCR stimulation
(Baba et al. 2003).
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So far, phosphorylation of actin on Y53 is known to exist in mouse neurons and is
particularly enriched at dendritic spines (Bertling et al. 2016; Bertling and Hotulainen 2017).
Dendritic spines are neuronal protrusions that can reorganize rapidly upon induction of a
process called long-term potentiation (LTP), which is important for learning and memory
formation (Bertling et al. 2016). In line with the fact that dendritic spines are characterized by
particularly short and dynamic actin filaments, actin pY53 increases filament turnover rate
and contributes to dynamic remodeling of the spines (Bertling et al. 2016). Moreover,
exogenous expression of a phospho-mimetic mutant actin (Y53E) prevented formation of
stable filaments and spine maturation, suggesting that dephosphorylation of actin may be
necessary in neurons to maintain stable actin structures (Bertling et al. 2016; Bertling and
Hotulainen 2017).
While systematic investigation of actin phosphorylation by mass spectrometry is so far
largely lacking, large-scale phospho-proteomic studies have provided ample evidence for
the existence a number of actin phosphorylation sites, and tyrosine phosphorylation in
particular, in a variety of different cell and tissue types: according to www.phosphosite.org, a
repository of high and low throughput studies that identify protein modifications (Hornbeck et
al. 2015), actin phosphorylation is most frequently identified on four sites: Y53 has over a
1000 references, and Y91, Y198 and Y294 have over 500 references each. Less frequently,
phosphorylation is also found on Y166, Y169, Y188 and Y218, while the only major serine
phosphorylation site is S52 (Hornbeck et al. 2015).
Actin pY53 is present in several non-small cell lung cancer (NSCLC) cell lines, together
with pY91, pY198 and pY294 (Rikova et al. 2007). Interestingly, actin was among the 50
most abundantly phosphorylated proteins in this study (Rikova et al. 2007) and
phosphorylation of actin at Y53 was reduced after treatment with gefitinib, an EGFR inhibitor
(Guo et al. 2008). However, given that previous studies had shown that actin is not directly
phosphorylated by EGFR (van Delft et al. 1995; Ohta et al. 1987), this may be due to an
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indirect effect, such as a kinase downstream of or dependent on EGFR, or off-target effects
from the inhibitor.
In breast epithelial cells, actin phosphorylation sites including pY53, pY91, pY169 and
pY198 were identified with and without EGF treatment (Heibeck et al. 2009). However, the
number of identified phosphorylated actin peptides was unchanged in treated and untreated
conditions, suggesting that, at least in this cell type, actin tyrosine phosphorylation levels are
not dependent on EGF treatment (Heibeck et al. 2009). Actin Y53 phosphorylation has also
been found in human B cells, leukemia, lymphoma, colorectal carcinoma and glioblastoma
cells as well as breast and ovarian cancer cells (Bennetzen et al. 2010; Lind, Artemenko,
and Pettersson 2012; Pighi et al. 2011; Chumbalkar et al. 2011; McKinley et al. 2013;
Mertins et al. 2014). Notably, in Jurkat T cells treated with ERK inhibitor U0126, many
phosphorylation sites were significantly decreased, including actin phosphorylation at Y53,
Y91, Y294 and Y362; however, only pY53 was decreased significantly at all timepoints
(Helou et al. 2013). Remarkably, in a deep phospho-proteomic study in HeLa cells, actin
phosphorylation at Y53 was found among the most abundant tyrosine phosphorylation sites
and showed an increase upon EGF stimulation, but not upon treatment with pervanadate, a
tyrosine phosphatase inhibitor (Sharma et al. 2014). Taken together, evidence from highthroughput mass spectrometry-based studies indicates that actin Y53 phosphorylation,
together with other actin tyrosine phosphorylation sites, is present in a variety of cell types
and tissues, including many cancer cells, and that its levels can vary depending on inhibitor
or growth factor treatment.
In summary, actin phosphorylation, in particular on tyrosine residues, has been identified
and studied for decades. Actin Y53 phosphorylation is best understood in D. discoideum,
where it is one of the most abundant tyrosine-phosphorylated proteins, affects actin
cytoskeletal structure and response of the amoeba to extracellular signals and nutrient
availability. Changes in actin tyrosine phosphorylation levels in mammalian cells in response
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to growth factors such as insulin (Machicao, Urumow, and Wieland 1983), EGF (Sharma et
al. 2014), as well as signaling-dependent processes like induction of long-term potentiation
(Bertling et al. 2016) and ERK inhibition (Helou et al. 2013) suggest that its levels may be
tightly controlled by kinase(s) and phosphatase(s) to finetune cellular signaling processes
and/or actin cytoskeletal structure, and more work is needed to determine the functions and
molecular mechanisms of actin tyrosine phosphorylation.

Other post-translational modifications of actin
Actin has also been found to harbor a diverse array of other post-translational
modifications including methylation of lysine, arginine and histidine residues, lysine
acetylation, ubiquitination, sumoylation, arginylation and redox-related modifications like
oxidation (Varland, Vandekerckhove, and Drazic 2019; Terman and Kashina 2013).
For example, actin methylation occurs on K84, is removed by the demethylase
ALKHBH4 and regulates actin-myosin interactions during cytokinesis (Li et al. 2013). Actin
histidine methylation on H73 regulates filament stability and ATP hydrolysis, is catalyzed by
the SETD3 methyltransferase and important for regulating uterine smooth muscle
contraction (Yao et al. 1999; Kwiatkowski et al. 2018; Wilkinson et al. 2019). Recently, we
showed that actin arginine mono-methylation at residue R256 is a conserved nucleusspecific actin PTM and exists in yeast, mouse and human cells as part of ATP-dependent
chromatin modifying complexes like INO80, and this modification is involved in active
transcription (Kumar et al. 2020). In another interesting recent study, actin was found to be
trimethylated on K68 by SETD2 methyltransferase in mammalian cells, and this methylation
appears to be important for regulation of actin polymerization and cell migration (Seervai et
al. 2020).
Acetylation of actin in Drosophila influences protein stability and polymerization (Berger
et al. 1981). In mammals, comprehensive studies of the acetylome have led to the discovery
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of new acetylation sites on actin, such as K61 (Choudhary et al. 2009; Kim et al. 2006; Zhao
et al. 2010). Interestingly, actin acetylation of K326 and K328 affects functional interactions
between F-actin, tropomyosin and myosin and may therefore play a role in muscle
contraction (Schmidt et al. 2020). Moreover, in another recent study, acetylated actin was
shown to play a role in inhibiting formin INF2 (A et al. 2019). This suggests that acetylation
of actin may be an important PTM with potential implications for filament dynamics.
Actin is also one of the major targets of the ATE1 enzyme that arginylates the actin Nterminus, which affects intracellular distribution of actin and polymerization and has been
implicated in heart development and neural crest cell migration in mice (Karakozova et al.
2006; Kashina 2014; Kurosaka et al. 2010; Pavlyk et al. 2018; Rai et al. 2008).
Ubiquitination is a post-translational modification characterized by the addition of the
small protein ubiquitin to lysine (or, less commonly, serine, threonine or cysteine) residues of
proteins and plays a role for signaling, protein localization and degradation (Kwon and
Ciechanover 2017). Actin ubiquitination was found in human skeletal muscle tissue and
several cell lines: Here, the E3 ligases MuRF1 and Trim32 ubiquitinate actin which leads to
proteasomal degradation and can decrease the number of contractile myofibrils and
promote their turnover (Polge et al. 2011; Kudryashova et al. 2005).
Sumoylation is the covalent attachment of SUMO (small ubiquitin-like modifier) to lysine
residues of target proteins (Yang et al. 2017). Actin sumoylation at K284 is present in vivo
and, together with sumoylation on K68, controls nuclear localization of actin by retaining the
sumoylated form in the nucleus (Hofmann et al. 2009). This is particularly interesting as the
mechanism of how actin stays in the nucleus had long been unknown.

In summary, actin is subject to a large number of different types of post-translational
modifications. While the roles of a few modifications have been explored, particularly with
regard to their effect on actin polymerization, systematic studies determining how actin
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PTMs are regulated by particular physiological states, whether they occur in a tissue-specific
manner and how they affect actin filament dynamics and other cellular processes, are still
lacking for most actin PTMs (Terman and Kashina 2013; Varland, Vandekerckhove, and
Drazic 2019). One particularly interesting question that is beginning to emerge is which actin
PTMs are localized to specific subcellular compartments, such as the cell nucleus; this is the
case for at least one arginine methylation site on actin (Kumar et al. 2020).
Another important concept, analogous to roles of PTMs in epigenetics (Musselman et al.
2012; Allis and Jenuwein 2016), is studying the ‘writers’, ‘erasers’ and ‘readers’ of actin
PTMs. While a few enzymes depositing (Wilkinson et al. 2019; Seervai et al. 2020; Kashina
2014) and removing (Li et al. 2013) actin PTMs have been identified, little is known about
actin PTM ‘reader’ proteins, and how they might serve as context-dependent actin-binding
proteins or connect actin PTMs to certain signaling pathways.

Roles of actin in human disease
Due to the ubiquitous expression and high importance of actin for a large number of
cellular and organismal functions, disruption of normal actin biology, either through defects
in actin regulation mechanisms or mutations of actin itself, can cause diseases: Mutations
are found in all six isoforms and have varying effects, depending on whether they are
somatic or germline mutations, and what residue(s) of the protein or region(s) of the gene
are affected (Parker, Baboolal, and Peckham 2020). For example, ACTA1 missense
mutations can cause Nemaline Myopathy, a skeletal muscle disease (Wallgren-Pettersson
et al. 2011), while ACTA2 (α-smooth muscle actin) missense mutations are linked to
hereditary thoracic aortic aneurysms as well as cerebral vascular disease (Guo et al. 2007;
Liu et al. 2017; Munot et al. 2012). ACTB (β-actin) and ACTG1 (γ-cytoplasmic actin)
mutations can cause a developmental disorder termed Baraitser-Winter syndrome
characterized by pleiotropic effects including intellectual disability and multiple organ defects
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(Parker, Baboolal, and Peckham 2020; Riviere et al. 2012). Notably, actin mutations are
enriched at particular features of the protein structure, such as the flexible D-loop in
subdomain 2 that is important for actin polymerization and interactions with ABPs (Parker,
Baboolal, and Peckham 2020). Additionally, several mutations are found at sites that have
been shown to be post-translationally modified: For example, M47 mutations, a residue
oxidized by MICAL, occur in several actin isoforms (Grintsevich et al. 2016; Parker,
Baboolal, and Peckham 2020). Mutations of the R256 residue that can be methylated are
associated with vascular diseases (Kumar et al. 2020; Liu et al. 2017).
In cancer, alterations of the actin cytoskeleton are critically important as they go along
with differences in cell migration, invasion and metastasis, and emerging evidence suggests
that altered actin expression levels are linked to tumorigenesis: For example, upregulation of
ACTB, ACTA2, ACTG1 and ACTC1 expression is found in various tumor types and often
associated with shorter survival, more aggressive tumors with higher metastatic capacity,
and chemoresistance, although decreased expression of some actin isoforms is also found
in certain cancer types (Suresh and Diaz 2021; Guo et al. 2013). It is important to note that
up- or downregulation of one or more actin isoforms can change the ratio of different actins
in the cell, which in turn can affect cell shape and migration due to their distinct
polymerization dynamics; in addition, changes in actin isoform expression can alter
interactions with ABPs and cause various downstream effects (Suresh and Diaz 2021).

While the diverse roles of actin isoforms in cancer and other diseases are not yet fully
understood, it is becoming more evident that actin is more than a ‘housekeeping’ protein
with structural roles and may play important roles in the pathogenesis of various diseases
through differential expression patterns (Guo et al. 2013), mutations affecting
polymerization, protein interactions, as well as through a diverse array of post-translational
modifications with distinct biological functions that have yet to be explored.
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Part Two: Phosphatidylinositol-3-kinase is an important transducer of growth signals

Classification of PI3K enzymes
Phosphatidylinositol-3-kinases (PI3Ks) are a family of intracellular lipid kinases that
phosphorylate phosphatidylinositol at the 3’ hydroxyl group to regulate cellular signaling
pathways (Bilanges, Posor, and Vanhaesebroeck 2019). PI3K enzymes have different
substrate specificities and, in mammals, are grouped into three classes based on their
domain structure and which substrates they prefer (Engelman, Luo, and Cantley 2006).
Class I PI3Ks are primarily involved in signal transduction, whereas Class II and III PI3Ks
are important for membrane trafficking and vesicle transport (Bilanges, Posor, and
Vanhaesebroeck 2019). In addition to their kinase activity, there is also evidence for PI3Ks
functioning as a protein-protein interaction scaffold that can help to stabilize proteins and
protein complexes (Costa and Hirsch 2010).
Class I PI3Ks are heterodimeric protein complexes that consist of a catalytic subunit and
a regulatory subunit. Unlike other PI3Ks, they are they only producers of PI(3,4,5)P3
phospholipids (Engelman, Luo, and Cantley 2006). Class IA encompasses the ‘classical’
PI3K enzymes (p110α, p110β and p110δ with their p85/p55 regulatory subunits) that
function downstream of receptor tyrosine kinases, G protein-coupled receptors (GPCRs)
and small GTPases (Figure 2), while Class IB consists of the p110γ catalytic subunit and
associates with p101 and p84 regulatory subunits (Fruman et al. 2017). Consistent with their
roles as signal transducers, they primarily act at the plasma membrane and early
endosomes, where their substrates (such as PI(4,5)P2) are found (Bilanges, Posor, and
Vanhaesebroeck 2019).
Class I PI3Ks are important regulators and their loss, either through knockouts or
specific inhibitors, has varied effects in different tissues. Both p110α and p110β are widely
expressed and knockout of either gene is early embryonic lethal (Taniguchi, Emanuelli, and
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Kahn 2006; Liu et al. 2009). Mice with a knockout of p110γ or p110δ survive longer, but
since the genes are mainly expressed in immune cells, their loss goes along with defects in
immune functions (Liu et al. 2009).

Figure 2. Class IA PI3K proteins and their domain structures. The regulatory subunits of
PI3K, p85α, p85β, and p55γ, as well as the p55α and p50α isoforms each contain two SH2
domains as well as an inter-SH2 region (iSH2) that interacts with the ABD domain of the
catalytic subunit. p85α and p85β also contain an SH3 and a BH (Rho GAP) domain. The
catalytic subunits p110α, p110β and p110δ contain an ABD (adaptor-binding domain), RBD
(Ras-binding domain) and C2 domain as well as a helical domain as well as the catalytic
domain of the enzyme. Protein domains were compiled with the help of the UniProt
database (UniProt 2021).
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The regulatory subunit p85
The regulatory subunits of Class IA PI3Ks are a family of multidomain proteins that,
together with the catalytic subunit, form the heterodimeric PI3K complex. The paralogs are
encoded by three genes: PIK3R1 for p85α, p55α, p50α, PIK3R2 for p85β, and PIK3R3 for
p55γ (Fruman et al. 2017). All Class IA regulatory subunits contain two Src Homology 2
(SH2) domains to bind to phosphorylated tyrosine residues, as well as a coiled-coil interSH2 (iSH2) region that is required for the interaction with the catalytic subunit (Fruman et al.
2017). Only p85α and p85β contain an SH3 domain and a BH domain in addition to the two
SH2 domains and the iSH2 domain (Fruman et al. 2017). All paralogs and their respective
domain architectures are depicted in Figure 2.
The p85 regulatory subunit has several important roles in PI3K regulation: First, p85
proteins associate with the catalytic subunits through their N-SH2 and iSH2 domains and
inhibit enzyme activity allosterically, until the inhibition is relieved when the N-SH2 domain
binds to phosphorylated tyrosine residues, for example on receptor tyrosine kinases like
EGFR or adapter proteins like IRS1; this binding event allows for a conformational shift that
dissociates binding between the N-SH2 domain and the catalytic subunit (Liu, Knapp, and
Ahmed 2014; Yu et al. 1998). The interaction with receptors or adaptor proteins also helps
to recruit PI3K from the cytosol to the cell membrane, in close proximity with its phospholipid
substrates (Bilanges, Posor, and Vanhaesebroeck 2019). Second, free catalytic p110
subunits are unstable and degraded when they are not bound to the regulatory subunit; for
this reason, most p110 exists bound to p85 proteins (Taniguchi, Emanuelli, and Kahn 2006).
Not all p85 isoforms and paralogs are expressed at equal levels: In mice, while p85α and
p85β are found in almost all tissues, p85β is usually less abundant than p85α; the Pik3r1
isoforms p55α and p50α are mostly found in the liver and skeletal muscle, and less
abundant than p85α (Taniguchi, Emanuelli, and Kahn 2006). p55γ, encoded by Pik3r3, is
expressed in lower levels than the other paralogs (Taniguchi, Emanuelli, and Kahn 2006).
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Interestingly, the regulatory subunit is often more abundant than the catalytic subunit,
which implies the existence of free p85 that is not bound to p110; this fact has been
investigated as a regulatory mechanism for PI3K activity, as free p85 can compete with the
PI3K heterodimer for phosphorylated tyrosine residues (Ueki et al. 2000; Cheung et al. 2015).
In addition, monomeric p85 has been shown to sequester phosphorylated IRS1 away from
the plasma membrane into cytoplasmic foci and thereby downregulate signaling (Luo et al.
2005). Lastly, free p85β can be ubiquitinated and degraded to increase PI3K signaling
(Kuchay et al. 2013). p85α and p85β also interact with other proteins through their N-terminal
SH3 and BH domains, for example c-Cbl, Rac1 and Cdc42 (Fang et al. 2001), suggesting that
p85 proteins may be a part of additional protein complexes and may have roles in signaling
pathways aside from their canonical function as a regulator of PI3K activity.
Unlike the genes for the catalytic subunits Pik3ca (p110α) and Pik3cb (p110β), whose
knockout is early embryonic lethal in mice, knockouts of the regulatory subunits Pik3r1
(p85α, p55α, p50α) and Pik3r2 (p85β) are viable but show phenotypes like insulin sensitivity,
muscle defects, hypoglycemia and liver necrosis (Fruman et al. 2000; Ueki et al. 2002; Liu
et al. 2009). Mice with knockouts of both Pik3r1 and Pik3r2 genes survive until E12.5, and in
MEFs from these organisms, p110α protein levels and PI3K activity are decreased, as p110
proteins are unstable when they are not bound to the regulatory subunit (Brachmann et al.
2005). However, in these MEFs, expression of Pik3r3 is upregulated, which is likely
sufficient to enable longer survival of double knockout embryos compared to knockouts of
the catalytic subunits (Brachmann et al. 2005).
In cancer, mutations of p85 have been described, but their effects differ depending on
which paralog is affected and the type of mutation (Rathinaswamy and Burke 2020). For
example, overexpression of PIK3R2 induces oncogenic transformation in fibroblasts
(Cariaga-Martinez et al. 2014), whereas loss of PIK3R1 is associated with tumor
progression (Thorpe et al. 2017), suggesting it acts in a tumor suppressor function. Point
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mutations in tumors are most frequently found in PIK3R1, albeit at a lower frequency than
mutations in PIK3CA (which encodes p110α). Specifically, they affect the iSH2 domain
region that mediates the interaction with p110 as well as the N-SH2 domain and may allow
for PI3K activity regardless of whether the N-SH2 domain is bound to a phosphorylated
tyrosine residue (Liu, Knapp, and Ahmed 2014). Mutations in the other paralogs (PIK3R2,
PIK3R3) are relatively rare compared to those in PIK3R1 (Liu, Knapp, and Ahmed 2014).

Upstream regulation of PI3K activity
Class IA PI3Ks are activated in response to a number of different signals and pathways.
They include receptor tyrosine kinases such as EGFR, PDGFR and INSR, GPCRs and
heterotrimeric G proteins, as well as Ras family GTPases; the latter function through
interactions with the Ras-binding domain (RBD) in the p110 protein, and each paralog has
preferences for certain GTPases (Fruman et al. 2017). For example, while p110α
preferentially interacts with Ras, p110β prefers RAC and CDC42 proteins; p110β is also
known to interact with Gβγ proteins dependent on GPCR activation, allowing it to integrate
signals from both RTKs and GPCRs (Fruman et al. 2017).
Mutations affecting PI3K activity are frequently found in human cancers. Most mutations
occur in PIK3CA, the gene encoding p110α, and often affect the helical and kinase domains
of the enzyme (Liu, Knapp, and Ahmed 2014). A common hotspot mutation is H1047R in the
kinase domain of p110α, which enables PI3K activation independent of Ras binding, while
E542K and E545K mutations alter the binding site of the N-SH2 domain to the enzyme and
enable enzyme activation independent of binding of the SH2 domain to phosphorylated
tyrosine residues (Liu, Knapp, and Ahmed 2014). Both types of mutations can lead to
activation of PI3K activity independent of upstream signals such as growth factors and result
uncontrolled growth and tumor formation (Fruman et al. 2017).
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Downstream effects of PI3K activity and the PI3K signaling pathway
PI3Ks phosphorylate the 3’ position of phosphatidylinositol. While phosphoinositides only
make up a small fraction of membrane phospholipids, they have important roles in cell
signaling and membrane dynamics (Bilanges, Posor, and Vanhaesebroeck 2019). Upon
activation of Class IA PI3Ks and their recruitment to the plasma membrane, the precursor
lipid PI(4,5)P2 is phosphorylated to PI(3,4,5)P3, a second messenger (Figure 3). A
complementary reaction can be carried out by PTEN, a tumor suppressor, that
dephosphorylates PI(3,4,5)P3 to PI(4,5)P2 (Liu et al. 2009). Alternatively, PI(3,4,5)P3 is a
substrate for SHIP1 and SHIP2 enzymes, resulting in dephosphorylation to PI(3,4)P2
(Pedicone et al. 2021).
After PI(3,4,5)P3 is generated, which occurs exclusively at the plasma membrane, but
not endosomal membranes, it can interact with pleckstrin homology (PH) domain-containing
proteins including protein kinases such as AKT, guanine nucleotide exchange factors
(GEFs) and other types of proteins (Lemmon 2007).
Subsequently, AKT becomes phosphorylated at T308 by PDK1 and at S473 by
mTORC2 (Figure 3) (Bilanges, Posor, and Vanhaesebroeck 2019). The active,
phosphorylated AKT can phosphorylate a large number of downstream targets, is one of the
main effectors of PI3K activity and mediates cell proliferation, survival, transcription
regulation, metabolic changes and cell migration (Manning and Cantley 2007). Among AKT
targets are cell cycle regulators p21 and p27, the apoptosis protein BAD, other protein
kinases such as GSK3α/β, and FOXO transcription regulators (Manning and Cantley 2007).
A major pathway is also through phosphorylation of TSC1 and TSC2, which inhibit RHEB,
an activator of mTORC1 (Figure 3); mTORC1 phosphorylates p70 S6K to activate protein
synthesis and cell growth (Bilanges, Posor, and Vanhaesebroeck 2019).
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Figure 3. The PI3K signaling pathway. A simplified overview of the PI3K signaling
pathway is depicted in which a growth factor (GF) binds to a receptor tyrosine kinase (RTK)
to recruit PI3K, which produces PI(3,4,5)P3 to activate Rho GTPase and AKT signaling.

While AKT signaling is clearly a major factor mediating PI3K activity, it is not required for
all downstream roles of PI3K activity in the cell; other signaling pathways such as MAPK
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signaling are also involved and, moreover, many steps of the pathway are part of an
extensive network of feedback loops, alternative activating signals and regulatory
mechanisms that together control the cellular response to PI3K activation (Castellano and
Downward 2011; Engelman, Luo, and Cantley 2006). For example, PI3K can mediate
activation of other signaling pathways independent of AKT, such as those regulating cell
migration, as accumulation of PI(3,4,5)P3 at certain areas of the cell membrane is one of the
factors that determine cell polarity and directional migration (Devreotes and Horwitz 2015).
However, whether PI3K activity is always required for directional migration is not completely
understood, as it has been shown that D. discoideum cells can still move towards
chemotactic stimuli even with knockouts of all PI3K and PTEN isoforms or in the presence of
a PI3K inhibitor, even though they migrate more slowly (Cain and Ridley 2009). In addition
to AKT, PI(3,4,5)P3 can also be bound by PH domains of RAC guanine nucleotide exchange
factors (GEFs), which are activators of the RAC GTPases, and mediate reorganization of
the cytoskeleton and cell migration (Lien, Dibble, and Toker 2017) (Figure 3). Given that
PI3K is upstream of many Rho GTPase regulators, it is likely that the role PI3K in migration
is mainly mediated through this protein class as well; nevertheless, a complex process like
cell migration is subject to multiple feedback mechanisms and PI3K activity may be involved
in more than one way (Cain and Ridley 2009).
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Part Three: The Rho GTPase guanine nucleotide exchange factor VAV2

Rho GTPases and their regulation
Rho (Ras homologous) GTPases are a family of small GTPases in the Ras superfamily
involved in cellular signal transduction, and in particular, in regulating the actin cytoskeleton
(Hodge and Ridley 2016). Rho GTPases exist in GTP-bound, active conformation or GDPbound, inactive conformations mediated by different types Rho GTPase regulating proteins:
Guanine nucleotide exchange factors (GEFs) mediate the exchange of GDP for GTP, which
activates the protein, whereas GTPase-activating proteins (GAPs) increase GTP hydrolysis
by the GTPase, which leads to inactivation (Hodge and Ridley 2016). A third type of
regulators are guanine nucleotide dissociation inhibitors (GDIs) that can prevent Rho
GTPase activation by sequestering the inactive forms in the cytosol (Hodge and Ridley
2016).
Generally, Rho GTPases are activated in response to extracellular stimuli and their
respective receptors, such as RTKs, GPCRs, integrins, cadherins and cytokine receptors
(Hodge and Ridley 2016). Interactions with their respective GEFs serve not only activate
them, but also to recruit them to the plasma membrane where they can interact with various
effectors: actin-regulating proteins, adaptor proteins and certain kinases, to mediate their
downstream functions (Hodge and Ridley 2016).
Among the best characterized classical Rho GTPases are RHOA, CDC42 and RAC1,
as well as their respective subfamily members (e.g. RAC2 and RAC3 in the RAC-like
subfamily) (Lawson and Ridley 2018). Briefly, RHOA regulates stress fiber formation and
focal adhesions by activating formins like mDia, as well as ROCK, which activates LIMK and
increases myosin light chain phosphorylation, to increase actin polymerization and
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actomyosin assembly (Hanna and El-Sibai 2013). RAC1 is important for formation of
lamellipodia, which are important for cell migration, through activating the WAVE complex,
the actin branching ARP2/3 complex and PAK, a serine/threonine kinase responsible for
MLCK phosphorylation and inhibition, resulting in increased actin polymerization, branching,
and release of capping proteins (Hanna and El-Sibai 2013). Lastly, CDC42 regulates
filopodia and cell polarity and through activating PAK, the WASP and WAVE complexes
(Hanna and El-Sibai 2013). Due to the fact that GEFs activate Rho GTPases, many have
been shown to have oncogenic activity when overexpressed or mutated in a way that
renders them independent of outside stimuli (Bustelo 2000).

VAV family proteins
GEFs are separated into two families: The larger DBL family GEFs are characterized by
a DBL-homology (DH) as well as a pleckstrin homology (PH) domain, while the DOCK family
of GEFs has fewer members and its members contain a DHR1 (Dock homology region 1)
and a catalytic GEF domain termed DHR2 (Rossman, Der, and Sondek 2005).
VAV proteins belong to the DBL family of GEFs and, in addition to the DH and PH
domains, they also contain a Calponin homology (CH) domain, an acidic region, a C1-like
zinc finger domain, an SH2 domain, and one or two SH3 domains (Figure 4) (Bustelo 2000).
While the DH domain is required for the GTP-GDP exchange with Rho GTPases, the PH
domain allows for binding to phosphoinositides including PI(3,4,5)P3 and membrane
recruitment. The CH domain and acidic region form an inhibitory module for VAV proteins
that interacts with the DH domain and prevents activation of Rho GTPases unless
phosphorylation of VAV at tyrosine residues in the acidic region relieves this inhibition
(Aghazadeh et al. 2000; Schmidt and Hall 2002). The main function of the VAV SH2 domain
is to recruit the protein to tyrosine-phosphorylated receptors like EGFR, PDGFR, BCR and
TCR (Bustelo 2000). The SH3 domains are important for VAV localization by mediating
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interactions with proline-rich motif-containing proteins, but there is also evidence that the Cterminal SH3 domain plays a role in regulating the catalytic activity of VAV by helping to
maintain an autoinhibited state (Barreira et al. 2014; Bustelo 2014).

Figure 4. Domain structure of VAV proteins. Human VAV family proteins are multidomain
proteins that feature a calponin homology (CH), a Dbl homology (DH) and a pleckstrin
homology (PH) domain, a zing finger (ZF) region, two SH3 domains and one SH2 domain.
Domain structures are similar for VAV1, VAV2 and VAV3. Protein domains were compiled
with the help of the UniProt database (UniProt 2021).

Notably, their unique domain structure with both SH2 as well as DH and PH domains
structure allows VAV proteins to couple tyrosine phosphorylation signaling with Rho GTPase
activation and thereby mediate a wide range of biological functions related to cytoskeletal
organization and cell signaling (Bustelo 2014).
The VAV protein family is well conserved and is found in vertebrates, as well as in
choanoflagellates, C. elegans and D. melanogaster, but not in S. cerevisiae (Dekel et al.
2000; Bustelo 2014). In mammals, there are three closely-related VAVs: VAV1, the first
identified family member, is specifically expressed in the hematopoietic system and a few
other cell types, whereas VAV3 is more broadly expressed and VAV2 is found in almost all
tissue types (Bustelo 2000, 2014).
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The role of VAV2 in signaling
The overlapping and distinct roles of VAV family members remain an open area of
investigation. While they all possess the same domain structures, non-redundant functions
could be mediated by tissue-specific expression, different specificities for certain interaction
partners and upstream regulators, as well as distinct subcellular localization (Bustelo 2014).
In mice, absence of Vav2 causes tachycardia, high blood pressure and defects in the
cardiovascular system and kidney function, likely due to its role in nitric oxide signalingmediated relaxation of blood vessels (Sauzeau et al. 2007; Sauzeau et al. 2010). In
contrast, loss of Vav1 leads to defects in lymphocyte biology, consistent with the expression
of Vav1 expression in the hematopoietic system, while Vav3 knockout mice have defects in
cerebellar and bone development (Bustelo 2014; Faccio et al. 2005; Tybulewicz 2005).
The VAV2 SH2 domain can bind to several tyrosine-phosphorylated proteins: There are
three ligands for which the binding mechanism to the domain has been structurally
characterized, ARAP3, a GAP for ARF6 and other Rho GTPases including RAC1 (Wu et al.
2012), as well as TXNIP (thioredoxin-interacting protein), a protein involved in regulation of
apoptosis and proliferation (Liu et al. 2016). Recently, interaction of the VAV2 SH2 domain
with a phosphorylated peptide from EphA2, a transmembrane receptor, was demonstrated
and also characterized by NMR (Ge et al. 2020). Additionally, the VAV2 SH2 has been
shown to mediate interactions with a phosphorylated cortactin, an actin-binding protein
(Rosenberg et al. 2017).

VAV2 is mostly described in the literature as a GEF for RAC1, but it has also been
shown to activate CDC42 and RHOA, and as a Rho GTPase regulator, it stimulates JNK
signaling, lamellipodia and membrane ruffle formation in mouse fibroblasts (Abe et al. 2000).
Importantly, VAV proteins, and VAV2 in particular, are connected to PI3K signaling as
well. VAV becomes phosphorylated on tyrosine residues by cytosolic kinases in response to
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receptor stimulation by certain extracellular ligands like insulin, or upon trans-activation by
cadherins (Uddin et al. 1995; Fukuyama et al. 2006; Crespo et al. 1997). To become fully
active, VAV2, but not VAV1 or VAV3, requires the PH domain, which can recognize
phospholipids produced by PI3K. When cells are treated with a PI3K inhibitor, VAV2 is not
activated efficiently, suggesting that it acts downstream of PI3K (Tamas et al. 2003;
Fukuyama et al. 2006). However, the mechanisms governing VAV2 activity appear to be
complex. For example, cell adhesion to fibronectin can activate both PI3K and VAV2;
however, under these conditions, tyrosine phosphorylation of VAV2 does not occur, which is
normally required for activation (Marcoux and Vuori 2003). Moreover, there is evidence for a
role of VAV2 upstream of PI3K in response to insulin stimulation, as expression of a
catalytically inactive VAV2 or knockdown of VAV2 reduced activation of downstream targets
of PI3K such as AKT and pS6K phosphorylation (Rodriguez-Fdez et al. 2020).
While some of these effects may be cell type or stimulus-dependent, they indicate that
PI3K and VAV2 signaling pathways are interconnected, and more investigation is needed to
fully understand their respective mechanisms of regulation and crosstalk in cell signaling
and regulation of cytoskeletal dynamics.
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Chapter II: RESULTS

29

Part One: Identification of potential actin pY53 ‘reader’ proteins

SH2 protein domain array reveals binding partners for actin tyrosine phosphorylation
sites
Post-translational modifications exert their functions in many different ways, including
through facilitating interactions with other proteins (Lothrop, Torres, and Fuchs 2013).
Binding partners often contain specialized ‘reader’ domains that allow for binding to
particular PTMs; this concept has been of particular importance for the study of histone
PTMs (Musselman et al. 2012).
We reasoned that one of the ways actin PTMs may be involved in cellular functions is by
facilitating interactions with PTM ‘reader’ domain-containing proteins. The largest family of
tyrosine phosphorylation ‘reader’ domains is the Src Homology 2 (SH2) domain that consists
of over 110 members in humans (Huang et al. 2008). Therefore, to find out whether actin
tyrosine phosphorylation sites may bind to SH2 domain-containing proteins, we decided to
use a protein domain array approach. Such arrays allow for simultaneous probing of dozens
to hundreds of different domains with a modified peptide of interest and detection of specific
interactions between peptide and domain (Chen, Sagum, and Bedford 2020). Protein
domain arrays have been successfully used in the past to identify PTM-dependent proteinprotein interactions, including SH2 domains (Levy-Apter et al. 2014; Roth et al. 2019).
To identify ‘readers’ for actin phosphorylation sites, 97 purified, GST-tagged SH2
domains from 86 different proteins (Figure 5C) were spotted in an array by the Protein Array
and Analysis (PAAC) core facility at MD Anderson Cancer Center (Director: Mark T.
Bedford, Ph.D.) and probed with a biotinylated actin peptide containing Y53
phosphorylation, as well as the unphosphorylated peptide as a control (Figure 5A, 5B). We
found that the actin pY53 peptide specifically binds to the N-terminal SH2 domain of
paralogs of the regulatory subunit of PI3K, p85α, p85β and p55γ, as well as the SH2 domain
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of the Rho GTPase guanine nucleotide exchange factor, VAV2. No binding was observed to
the unphosphorylated peptide, indicating that the interaction is tyrosine phosphorylationdependent.
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Figure 5. Identification of actin pY53 peptide interactions with SH2 domains. (A) SH2
protein domain array probed with unmodified peptide around actin Y53 shows no binding to
any SH2 domains. (B) Protein domain array probed with actin pY53 peptide shows specific
binding to the N-terminal SH2 domains of p85α (PIK3R1_N; C), p85β (PIK3R2_N; B), p55γ
(PIK3R3_N; A) and the SH2 domain of VAV2 (VAV2; D). (C) Overview of the PhosphoTyrosine Binding SH2 Domain Array 2.1, as provided by the PAAC. Data for all panels were
generated by Cari Sagum (PAAC, MD Anderson Cancer Center).
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In addition to screening actin pY53 peptides on the array, we also used peptides for
other phosphorylation sites on actin that are less well studied, but frequently found by
phospho-proteomic studies, to provide a more complete picture of actin tyrosine
phosphorylation ‘readers’. Specifically, peptides containing pY91, pY198, and pY294
phosphorylation sites were probed on the array by the PAAC (Figure 25), as these are the
most frequently identified sites with over 500 references each, according to the PhosphoSite
Plus database (Hornbeck et al. 2015).
The strongest interaction for the pY91 peptide as well as the pY198 peptide is with the
SH2 domain of CRK (Figure 25), an adaptor protein involved in multiple signaling pathways
(Kiyokawa et al. 1997). Probing of the array with the actin pY294 peptide revealed binding to
a number of SH2 domains including those of ABL1, ABL2 and GRAP (Figure 25). Weak
binding of the peptide to the GRB2 SH2 domain was also observed. Interestingly, this SH2
domain is known to prefer a pYXNX motif (Huang et al. 2008), which the actin pY294
peptide contains.
Taken together, we identified several potential interaction partners for actin tyrosine
phosphorylation sites using the SH2 domain array. While some of the peptides bind to the
same domains, most of them with a specific subset of domains, suggesting that some
degree of binding specificity for particular domains is conferred by the peptide sequence
alone.
Given that actin Y53 phosphorylation is not only the most frequently identified
phosphorylation site on actin, but also the site with the most evidence of functional
relevance, we decided to continue investigating the potential actin pY53 ‘reader’ proteins,
the p85 paralogs and VAV2.
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Validation of protein domain array results by peptide pull-down
To begin validating the findings from the protein domain array, I performed peptide pulldowns with GST-tagged SH2 domains. The domains for peptide pull-down assays were
purified from E. coli BL21 strains using standard small-scale glutathione affinity purification
(see Chapter IV: Materials and Methods). An example of protein purification is shown in
Figure 6A and 6B. The purified SH2 domains were then added to streptavidin beads that
had been coupled to either the phosphorylated or unphosphorylated actin Y53 peptides and
the eluted proteins were detected by western blot with antibodies against GST. Using this
assay, I found that all four SH2 domains (p85α, p85β, p55γ and VAV2) were able to
specifically bind to the actin pY53 (Figure 6C). There was no binding of the
unphosphorylated peptide or the beads with no peptide to any of the domains. This result
confirmed the findings from the protein domain array and suggests that the interaction
between the peptide and the SH2 domains is indeed dependent on the phosphorylation.
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Figure 6. Actin pY53 peptide binds to GST-tagged SH2 domains. Examples of
purification of GST-tagged SH2 domains of (A) p85α and (B) p85β for peptide pull-down.
Fractions of each purification step after lysis and centrifugation were collected, resolved by
SDS-PAGE and stained with Coomassie Blue (S: supernatant, P: pellet, FT: flow-through
from GST beads, W1: first wash, W2: second wash, E: eluate. Purification of VAV2 and
p55γ N-SH2 domains was performed in a similar manner (not shown). (C) Peptide pull-down
results for all four SH2 domains. Pull-down of each domain was performed with either beads
only (no peptide), unmodified actin Y53 peptide (Y53), or phosphorylated actin pY53 peptide
(pY53).
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Validation of protein domain array results by ITC measurements
Peptide pull-down can inform about binding specificity, but it has limited ability to
quantitatively measure interaction affinities. Therefore, we decided to confirm our findings
with Isothermal Titration Calorimetry (ITC). ITC is a technique used to determine
thermodynamic parameters (binding affinity, stoichiometry and enthalpy changes) of
interactions between molecules in solution, such as small molecule inhibitors, peptides,
proteins or DNA and has been used successfully for SH2 domain-phosphopeptide
interactions (Panayotou and Ladbury 2001). Importantly, ITC is quantitative and can
therefore be used to compare binding parameters between different protein domains with
the same peptide and vice versa. In brief, during an ITC experiment, the ligand (in our case
the actin peptide) is added in small aliquots to the sample cell that contains the other binding
partner (in our case the SH2 domain). Binding between the two molecules causes changes
in temperature that can be measured by the instrument and analyzed to yield the
thermodynamic parameters of the interaction.
For ITC, large scale protein expression was performed in E. coli BL21 strains. The
proteins were extracted, the GST tag removed and purified with FPLC (see Chapter IV:
Materials and Methods) and ITC measurements were performed for the SH2 domains from
p85α, p85β and VAV2 by Shaobo Dai, Ph.D. (Dr. Xiaodong Cheng’s laboratory). The results
correlated well with protein domain array and peptide pull-down results and confirmed that
binding is specific to the phosphorylated peptide for all three domains. At first, ITC was
performed with a longer (17 amino acid) peptide with an N-terminal biotin tag, which had
been used for the protein domain array. We found that the interaction affinity was 4.6 ±
0.6 µM for p85α N-SH2, 2.2 ± 0.5 µM for p85β N-SH2 and 3.7 ± 0.6 µM for VAV2 (Table 7,
Appendix). In a second step, a shorter peptide (9 amino acids) without a biotin tag was
used, which is more similar to peptides used in other studies with the same SH2 domains
(Nolte et al. 1996). Because it is well established that SH2 domains only have one peptide
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binding site, we set the stoichiometry to N = 1 and calculated the resulting interaction
affinity: 5.2 ± 2.0 µM for p85α and 1.1 ± 0.3 µM for p85β N-SH2 (Figure 7A, 7B). VAV2 SH2
showed an affinity of 1.9 ± 0.6 µM for the actin pY53 peptide (Figure 7C). No binding was
detected for the unphosphorylated peptides (data not shown). All thermodynamic
parameters are listed in Table 1, and thermodynamic parameters for without adjusting the
stoichiometry are listed in Table 6 (Appendix).
Given that for most SH2 domains, the interaction affinity to their peptide ligands is in the
low micromolar range (from around 0.1 µM to around 10 µM) (Ladbury and Arold 2011), our
results suggest that the actin peptide binding to the domain fits within the expected range of
binding affinities.
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Figure 7. ITC measurements of actin pY53 peptide binding to SH2 domains. (A) Raw
ITC data (top panel) and integrated curve (bottom panel) for p85α N-SH2 domain
(measurement cell) binding to actin pY53 peptide (KDSpYVGDEA; titrant). (B) Raw ITC data
(top panel) and integrated curve (bottom panel) for p85β N-SH2 domain binding
(measurement cell) to actin pY53 peptide (KDSpYVGDEA; titrant). (C) Raw ITC data (top
panel) and integrated curve (bottom panel) for VAV2 SH2 domain (measurement cell)
binding to actin pY53 peptide (KDSpYVGDEA; titrant). Data for all panels were generated by
Dr. Shaobo Dai (Dr. Xiaodong Cheng laboratory, MD Anderson Cancer Center).

Table 1. Thermodynamic parameters of ITC experiments with actin pY53 peptide.
Protein

p85α N-SH2

p85β N-SH2

VAV2 SH2

KD (µM)

5.2 ± 2.0

1.1 ± 0.3

1.9 ± 0.6

Na

1

1

1

ΔG (kcal/mol)

-7.21

-8.12

-7.82

ΔH (kcal/mol)

-7.56

-6.63

-7.44

-TΔS (kcal/mol)

0.352

-1.49

-0.379

Peptide: KDSpYVGDEA
a
Stoichiometry of the interaction has been set to N = 1. Data without this adjustment are found in
Table 6 (Appendix).
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Part Two: Structural characterization of the interactions of actin pY53 with p85α, p85β
and VAV2 SH2 domains

Generation of structures using X-ray crystallography
As a next step, we aimed to gain a better understanding of the mechanism that underlies
the interaction between the actin pY53 peptide and the p85 and VAV2 SH2 domains through
structural analysis. To this end, we set out to solve co-crystal structures of the p85α and
p85β N-SH2 and VAV2 SH2 domains bound to an actin pY53 peptide. Protein purification
for crystallization (the same as for ITC measurements), crystallization and structure
refinement was performed by Shaobo Dai, Ph.D., and Dr. Xiaodong Cheng’s laboratory. At
first, we performed optimization of the expression constructs. An SH2 expression construct
in the pGEX-6P-1 backbone contained additional sequence at the N- and C-terminus, which
produced a structure that did not contain the peptide, except for VAV2 SH2 domain where
three residues of the actin peptide (S-pY-V) were resolved. To solve this issue, in a next
step, we used a shorter actin peptide (9 amino acids) without a biotin tag. Again, we only
obtained structures of the p85α and p85β N-SH2 domains without the peptide, and a crystal
structure for VAV2 SH2 domain with the five residues of the peptide. Upon closer analysis of
the p85α and p85β structures, we noticed interference of C- and N-terminal residues of the
symmetry mate in the crystal with the peptide binding site. Therefore, I generated
expression constructs with a shorter overhang in a different backbone (pGEX-4T-1 instead
of pGEX-6P-1) as the former contains a thrombin cleavage site instead of a PreScission
cleavage site to remove the GST tag and results in a shorter N-terminal overhang of amino
acids that could interfere with peptide binding. This approach resulted in a high-resolution
crystal structure with the entire actin peptide resolved for p85α. However, for p85β, Cterminal residues belonging to the SH2 domain itself and not the backbone also interfered
with peptide binding to symmetry mates. Therefore, the sequence encoding three C-terminal
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residues of the domain (QQD) was deleted in the expression construct for p85β N-SH2,
which solved the issue of interference with peptide binding in the crystal and we obtained a
high-resolution crystal structure for p85β N-SH2 containing the complete actin peptide.

Actin pY53 binds to p85α N-SH2 with a partially unique mechanism
We obtained a 1.14 Å crystal structure for the p85α N-SH2 domain bound to the actin
peptide (Figure 8A). Data collection and refinement statistics are listed in Table 2. The
crystal structure shows a characteristic SH2 domain fold characterized by central,
antiparallel β-sheets (βB - βD) and one α-helix on each side (αA, αB). The peptide is
oriented approximately perpendicular to the β-sheets, as is commonly seen for SH2 domainpeptide interactions. The two peptide residues N-terminal of the phospho-tyrosine and three
residues C-terminal of the phosphotyrosine adopt a relatively straight, extended
conformation, whereas the final N- and C-terminal residues of the peptide are oriented
outwards, away from the SH2 domain (Figure 8A, Figure 26B).
Peptide binding is achieved through a number of hydrogen bonds involving both the side
and main chains of peptide residues. The phosphorylated tyrosine of the peptide forms polar
contacts with R340, R358, S361 and T369 of the domain (Figure 8B). However, K382 of the
domain, which binds pY in some published structures (Nolte et al. 1996) does not bind to the
actin pY53 in our structure. Additional polar contacts exist with L380, which engages the
main chain of S52 and V54 of the actin peptide. Notably, N378 of the domain binds to D51
of the peptide (Figure 8C), a feature that is not observed in the p85α N-SH2 domain
structures with pTyr peptides of PDGFR or CD28 (Nolte et al. 1996; Inaba et al. 2017).
Moreover, the hydroxyl group of Y416 of the domain engages the V54 main chain of the
peptide and is oriented outwards, toward the peptide (Figure 8D). In the other structures,
this residue is oriented inwards, toward the center of the SH2 domain an is part of the deep
hydrophobic pocket that engages a methionine residue of the peptide (Nolte et al. 1996).
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The C-terminus of the peptide forms contacts with N417 and K419 of the domain. However,
due to the fact that these interactions are at the C-terminus of the peptide, it remains
uncertain whether they could also appear in binding of the full-length protein. In the crystal
structure, the N-terminal (K50) and C-terminal residues (A58) of the peptide are in close
proximity to symmetry mates. Therefore, their orientation and interactions may be partially
influenced by their surroundings in a non-physiological manner.

Importantly, the consensus motif for phosphorylated ligands binding to the p85α N-SH2
domain is a pYXXM motif, with X denoting any amino acid (Songyang et al. 1993). This
enables a two-pronged binding mechanism consisting of the phosphorylated tyrosine and
the hydrophobic methionine that is inserted in a relatively deep hydrophobic pocket in the
domain. Actin, however, does not contain a methionine at the +3-position relative to the
phosphotyrosine, but an aspartate residue. In our structure, this residue is oriented away
from the domain and does not form any hydrogen bonds (Figure 8D). This finding suggests
that the interaction with actin is mediated by a mechanism partially distinct from the
canonical one, and that both N378 and Y416 residues of the domain might be particularly
important for the interaction with the actin pY53 peptide.
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Figure 8. Crystal structure of actin pY53 peptide bound to the p85α N-SH2 domain. (A)
Cartoon view of p85α N-SH2 domain bound to actin pY53 peptide. Note the general SH2
domain fold with three central β-sheets (βB, βC, βD) and one α-helix on each side (αA, αB).
(B) Interaction of the phosphorylated tyrosine of actin with residues of the domain (R340,
R358, S361, T369). (C) Interaction of D51 and V54 of the actin peptide with N378 and L380
of the domain, respectively. (D) Interaction of main chains of V54 and G55, D56 with side
chains of Y416 and N417 of the domain, respectively. Crystal structures were generated by
Dr. Shaobo Dai (Dr. Xiaodong Cheng laboratory, MD Anderson Cancer Center).
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Table 2. Data collection and refinement statistics for p85α.
SH2 domain
Actin peptide
Beamline
Space group
Cell dimensions (Å)
Resolution (Å)
a
Rmerge
Rpim
CC1/2
b
<I/σI>
Completeness (%)
Redundancy
Observed reflections
Unique reflections
Refinement
Resolution (Å)
No. reflections
c
Rwork / d Rfree
No. Atoms
Protein
Peptide
Solvent
B Factors (Å2)
Protein
Peptide
Solvent
R.m.s. deviations
Bond lengths (Å)
Bond angles (˚)

p85α (N-terminal)
KDSpYVGDEA
Rigaku MicroMax-003 Microfocus sealed tube X-ray
generator (wavelength 1.54 A)
P212121
43.8, 46.5, 50.1
a=b=g=90°
26.9-1.14 (1.18-1.14)
0.054 (0.650)
0.027 (0.429)
0.981 (0.512)
13.8 (1.3)
97.6 (79.5)
4.4 (2.7)
163,655
37,579 (3027)
1.14
37,549
0.131 / 0.146
1927
140
220
10.2
14.6
22.8
0.009
1.20

* Values in parenthesis correspond to highest resolution shell.
a
Rmerge = Σ | I - <I>| /Σ I, where I is the observed intensity and <I> is the averaged intensity from
multiple observations.
b
<I/σI> = averaged ratio of the intensity (I) to the error of the intensity (σI).
c
Rwork = Σ | Fobs - Fcal | /Σ | Fobs |, where Fobs and Fcal are the observed and calculated structure
factors, respectively.
d
Rfree was calculated using a randomly chosen subset (5%) of the reflections not used in refinement.
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To further validate these findings, I generated expression constructs for the p85α N-SH2
domain harboring mutations to test which residues are important for the interactions in a
peptide pull-down assay. An R358A mutation serves as a control as this residue is important
for binding to the pY itself (Figure 8B) and is expected to strongly reduce binding of the
phosphorylate tyrosine (Luo et al. 2005). I also generated a construct harboring N378A and
Y416F mutations, as these residues appear to be relevant for the interaction with the actin
peptide (Figure 8C, 8D). The peptide pull-down assay was performed with both the actin
pY53 peptide as well as a peptide from PDGFR around a phosphorylation site at Y751,
which had been previously shown to bind to the p85α N-SH2 domain in a crystal structure
(Nolte et al. 1996).
My results show that the p85α R358A mutation indeed leads to a strong reduction in
binding for both the actin pY53 as well as the PDGFR pY751 peptides (Figure 9). Notably,
the effect was more pronounced for the actin peptide, suggesting that the R358 residue may
be more important. This could potentially be due to the fact that the actin phospho-tyrosine
is bound by fewer residues that the PDGFR phospho-tyrosine, as K382 of the domain does
not form a contact with actin pY53, and therefore loss of R358 may have a stronger effect.
Importantly, a detectable reduction in binding to the actin peptide was observed with the
N378A-Y416F mutant SH2 domain, but not as much for the PDGFR peptide (Figure 9). This
result helps to validate the findings from the crystal structure and suggests that the two
residues are indeed more important for the interaction with actin than PDGFR, and point
toward a partially distinct interaction mechanism.
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Figure 9. Peptide pull-down with mutant p85α N-SH2 domains. Peptide pull-down was
performed with GST-tagged p85α N-SH2 domain constructs that are either WT, or have
R358A single mutation or N378A-Y416F double mutation. Biotinylated (17 amino acid)
peptides around actin pY53 or PDGFR pY751 were used for the experiment, and western
blot was performed using anti-GST antibodies, as well as Streptavidin-HRP to detect the
peptide.
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N-SH2 domains of p85α and p85β bind to actin pY53 in a similar manner
Our protein domain array, peptide pull-down and ITC results showed that the actin pY53
peptide not only binds to the N-SH2 domain of p85α, but also its paralog p85β. As described
above, the affinity of the peptide to the p85β N-SH2 domain is higher than to p85α,
suggesting that there may be differences in the binding mechanism between the two
domains. While the amino acid sequence between both SH2 domains is well conserved
( ∼ 85 % identical), this does not exclude the possibility that minor changes in protein folding
could translate to a slightly different binding mechanism. Moreover, no high-resolution
structure of the p85β N-SH2 domain with a peptide ligand has been deposited to PDB to
date. Therefore, we aimed to solve the crystal structure for p85β bound to the actin pY53
peptide.
We obtained a 1.5 Å crystal structure for the p85β N-SH2 domain bound to the actin
pY53 peptide (Figure 10A, Figure 26C). Data collection and refinement statistics are shown
in Table 3. All 9 amino acids of the peptide were resolved in one of the molecules, whereas
partial peptides with 5, 7 and 8 residues, respectively, were present in the three other
molecules in the asymmetric unit cell. Similar to the p85α, the p85β SH2 domain displays a
typical SH2 fold consisting of central β-sheets and one α-helix on each side connected by
loops and the peptide is oriented approximately perpendicular to the β-sheets (Figure 10A,
Figure 26).
Binding of the phosphorylated tyrosine is achieved by polar contacts with R358, S361
and T369 of the domain, similar to p85α (Figure 10B). Of note, R340 only engages with the
phosphorylated tyrosine in two of the four domains in the asymmetric unit cell (Figure 10C).
However, the two domains for which the contact is missing are oriented directly opposite to
each other, with the two peptides in close proximity to each other. For these two molecules,

47

the R340 residue engages with the neighboring SH2 domain, but not the peptide, which
could be due to crystallization artifacts.
Other parts of the peptide aside from the phosphorylated tyrosine are bound in a manner
similar to the p85α structure. In all four molecules in the asymmetric unit cell, the main chain
of V54 of the peptide forms a polar contact with Y416 of the domain, which is oriented
outwards, similar to the p85α structure (Figure 10F). In three of the four molecules, the N378
residue forms contacts with D51 of the peptide, as it does in our p85α structure
(Figure 10D). Moreover, in two of the four molecules, the N344 residue of the domain is
involved in binding of D51 of the peptide as well (Figure 10E), while this contact is not
present for p85α.
As no published structures for the p85β N-SH2 domain with other peptides are available
for comparison, it is unclear whether the p85β N-SH2 domain can bind other ligands in a
similar manner to actin pY53. However, as the p85β N-SH2 domain prefers substrates with
a pYXXM motif as well (Huang et al. 2008), and given the high similarity in binding
mechanism between p85α and p85β for the actin peptide, it is conceivable that the
combined involvement of both N378 and Y416 residues of the domain in peptide binding is
particularly important for actin binding, and perhaps other unknown ligands, for both SH2
domains.
Unlike our structure for p85α bound to the actin pY53 peptide, interactions with other
molecules in both the asymmetric unit cell as well as with symmetry mates are more
prominent in the p85β crystal structure, particularly for the C-terminal residues of the
peptide. For this reason, our results have to be interpreted with caution, as some of the
differences we observed may be due to crystal packing artifacts rather than true differences
in binding mechanism that would also occur in solution. Nevertheless, comparing both
structures shows that the main polar contacts we observed in the p85α structure are present
for p85β as well, and both peptides bind in a similar manner. However, determining whether
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any of the minor changes we observed are sufficient to explain the differences in binding
affinity will require further investigation.
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Figure 10. Crystal structure of actin pY53 peptide bound to p85β N-SH2 domain. (A)
Structure of p85β N-SH2 domain bound to actin pY53 peptide. Note the general SH2
domain fold with central β-sheets (βB, βC, βD) and one α-helix on each side (αA, αB). (B)
Interaction of the phosphorylated tyrosine of actin (chain F) with residues of the domain
(chain E) R358, S361 and T369. (C) Interaction of the phosphorylated tyrosine of actin
(chain H) with residues of the domain (chain G) R340, R358, S361 and T369. (D) Interaction
of D51 and V54 of the actin peptide (chain F) with N378, R340 and L380 of the domain
(chain E). (E) Interaction of D51 and V54 of the actin peptide (chain D) with N378, R340,
N344 and L380 of the domain (chain C), respectively. (F) Interaction of main chains of V54
and G55, D56, E57 of the actin peptide (chain F) with residues Y416, N417 and A418 of the
domain (chain E). All crystal structures were generated by Dr. Shaobo Dai (Dr. Xiaodong
Cheng laboratory, MD Anderson Cancer Center).
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Table 3. Data collection and refinement statistics for p85β.
SH2 domain
Actin peptide
Beamline
Space group
Cell dimensions (Å)
Resolution (Å)
a
Rmerge
Rpim
CC1/2
b
<I/σI>
Completeness (%)
Redundancy
Observed reflections
Unique reflections
Refinement
Resolution (Å)
No. reflections
c
Rwork / d Rfree
No. Atoms
Protein
Peptide
Solvent
B Factors (Å2)
Protein
Peptide
Solvent
R.m.s. deviations
Bond lengths (Å)
Bond angles (˚)

p85β (N-terminal)
KDSpYVGDEA
SER-CAT, 22-ID, wavelength=1Å
C2
188.1, 41.4, 65.8
a=g=90°, b=100.3°
34.9-1.45 (1.50-1.45)
0.160 (0.659)
0.068 (0.411)
0.991 (0.690)
11.8 (1.6)
89.7 (50.7)
4.5 (1.7)
355,291
79,846 (4,489)
1.45
79,820
0.190 / 0.222
3526
234
436
20.3
30.4
32.6
0.005
0.84

* Values in parenthesis correspond to highest resolution shell.
a
Rmerge = Σ | I - <I>| /Σ I, where I is the observed intensity and <I> is the averaged intensity from
multiple observations.
b
<I/σI> = averaged ratio of the intensity (I) to the error of the intensity (σI).
c
Rwork = Σ | Fobs - Fcal | /Σ | Fobs |, where Fobs and Fcal are the observed and calculated structure
factors, respectively.
d
Rfree was calculated using a randomly chosen subset (5%) of the reflections not used in refinement.
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Analysis of actin pY53 binding to VAV2 SH2 domain
In order to better understand the binding mechanism of the actin pY53 peptide not only
to the p85 SH2 domains, but also to the VAV2 SH2 domain we identified on the protein
domain array, we intended to solve the crystal structure for this domain as well. The SH2
domain of VAV2 had been structurally analyzed before, for example with peptides from
ARAP3 by NMR and a TXNIP peptide by X-ray crystallography (Wu et al. 2012; Liu et al.
2016).
We obtained a crystal structure for the VAV2 SH2 domain with a resolution of 2.2 Å.
Data collection and refinement statistics are listed in Table 4. In this structure, only five
residues of the peptide were resolved (Figure 11A, Figure 26D). The peptide is bound by the
domain primarily through polar contacts between the phosphate group and arginine residues
of the domain (R680, R698, R700) (Figure 11B), as well as hydrophobic interactions of V54
of the peptide with the pY+1 binding pocket of the domain (K718, I720, F756, L759) (Figure
11C). R680 of the domain also forms a bond with S52 of the peptide, in addition to the
phosphate group. Another polar contact is present between the main chain of H719 of the
domain and the main chain of V54 of the peptide. Moreover, the aromatic ring of pY53 is
packed in between H719 and K721 residues of the domain.
Notably, compared to our crystal structures for p85α and p85β N-SH2 domains, only five
residues of the peptide can be seen in our VAV2 SH2 domain structure, and only three of
them (S52, pY53, V54) engage with the domain. The C-terminal residues of the visible
peptide (G55, D56) are oriented outwards (Figure 11C), instead of occupying the pY+3
binding pocket of the domain. This could either represent the actual binding mechanism of
the peptide to the domain, or an artifact from crystallization. It is possible that only three
residues of the actin peptide interact and the other residues do not contact the domain, and,
for this reason, may be too flexible to be resolved in the crystal structure. However, this
raises the question of whether this limited interaction is sufficient to maintain binding
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specificity. Interestingly, aside from the lack of binding to the pY+3 pocket, this interaction
mechanism is quite similar to that of the TXNIP peptide to the VAV2 SH2 domain (Liu et al.
2016). In that structure, the main peptide-domain interaction is also mediated by the
residues immediately adjacent to the pTyr (Cys at pY-1 and Met at pY+1). In addition, the
TXNIP peptide has a valine residue at the pY+3 position, which binds to a dedicated pocket
of the domain. The other peptide residues are oriented outwards, away from the domain. Of
note, the TXNIP pY+1 methionine residue is hydrophobic, like the actin pY+1 valine residue,
whereas the pY-1 residue is cysteine for TXNIP and serine for actin, which are structurally
similar. Taken together, actin and TXNIP peptides bind to the VAV2 SH2 domain with a
strikingly similar mechanism and peptide orientation, suggesting that this set of interactions
may define a (partial) binding motif governing interactions of phosphorylated tyrosine
residues with the VAV2 SH2 domain.
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Figure 11. Crystal structure of partial actin pY53 peptide bound to VAV2 SH2 domain.
(A) Structure of VAV SH2 domain bound to actin pY53 peptide. Note the general SH2
domain fold with three central β-sheets (βB, βC, βD) and one α-helix on each side (αA, αB).
(B) Interaction of the phosphorylated tyrosine of actin with residues of the domain (R680,
R698, R700). (C) Interaction of S52 of the actin peptide with R680 and H719 of the domain,
and insertion of V54 of the peptide in binding pocket formed by K718, I720, F756 and L759

55

residues of the domain. All crystal structures were generated by Dr. Shaobo Dai (Dr.
Xiaodong Cheng laboratory, MD Anderson Cancer Center).

Table 4. Data collection and refinement statistics for VAV2.
SH2 domain
Actin peptide
Beamline
Space group
Cell dimensions (Å)
Resolution (Å)
a
Rmerge
Rpim
CC1/2
b
<I/σI>
Completeness (%)
Redundancy
Observed reflections
Unique reflections
Refinement
Resolution (Å)
No. reflections
c
Rwork / d Rfree
No. Atoms
Protein
Peptide
Solvent
B Factors (Å2)
Protein
Peptide
Solvent
R.m.s. deviations
Bond lengths (Å)
Bond angles (˚)

VAV2
KDSpYVGDEA
Rigaku MicroMax-003 Microfocus sealed tube
X-ray generator (wavelength 1.54 A)
C222
61.5, 109.4, 41.8
a=b=g=90°
26.8-2.15 (2.23-2.15)
0.151 (1.499)
0.044 (0.580)
0.987 (0.312)
10.3 (1.1)
96.1 (77.3)
13.1 (8.1)
101,054
77,15 (5,024)
2.15
7,685
0.234 / 0.273
869
41
45
41.5
45.1
46.8
0.002
0.472

* Values in parenthesis correspond to highest resolution shell.
a
Rmerge = Σ | I - <I>| /Σ I, where I is the observed intensity and <I> is the averaged intensity from
multiple observations.
b
<I/σI> = averaged ratio of the intensity (I) to the error of the intensity (σI).
c
Rwork = Σ | Fobs - Fcal | /Σ | Fobs |, where Fobs and Fcal are the observed and calculated structure
factors, respectively.
d
Rfree was calculated using a randomly chosen subset (5%) of the reflections not used in refinement.
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Part Three: Analysis of interactions of actin with p85 and VAV2 in human cells

Actin pY53 peptide binds to p85α and VAV2 in HEK293 cells
First, to test whether the actin pY53 peptide can interact with full-length p85 and VAV2
proteins in the context of a cell lysate, I performed peptide pull-down assays with HEK293
cell lysate followed by western blot detection of interacting proteins. I found that HA-tagged
p85α (Figure 12A) as well as endogenous VAV2 (Figure 12B) proteins can interact with the
phosphorylated actin pY53 peptide whereas there is no detectable binding to the
unphosphorylated peptide. These results suggest that the actin peptide around the Y53
residue can indeed bind to the full-length proteins in a phosphorylation-specific manner,
likely through their SH2 domains, in the context of a complex cell lysate.
However, the peptide represents only a small fraction of the protein and is uniformly
phosphorylated or unphosphorylated, which is likely not the case in cells. Nonetheless,
these results provide further evidence that specificity of p85α and VAV2 proteins for only the
phosphorylated peptide is maintained in the context of a cell lysate, and that the peptide can
bind to the full-length proteins and not just the isolated SH2 domains.
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Figure 12. Peptide pull-down of full-length proteins from HEK293 cell lysate. (A)
Peptide pull-down with biotinylated (17 amino acid) actin peptides (Y53, pY53) or beads only
(no peptide) using whole cell lysate from HEK293 cells transfected with HA-tagged fulllength p85α. Western blot was performed using anti-HA antibody. (B) Peptide pull-down with
biotinylated (17 amino acid) actin peptides (Y53, pY53) or beads only (no peptide) using
whole cell lysate from HEK293 cells. Western blot was performed using an antibody against
endogenous VAV2.
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Analysis of the interaction between p85β and actin in HEK293 cells
As a next step, I wanted to test whether the interaction can also be detected between
both full-length proteins. To this end, I expressed β-actin with an N-terminal FLAG tag in
HEK293 cells to facilitate detection and efficient immunoprecipitation. Antibodies for
endogenous actin tended to be less efficient at immunoprecipitating the protein (data not
shown) and one commonly used and highly specific antibody for all actin isoforms (C4) has
an epitope around the residues 50 - 70 in the actin sequence (Lessard 1988), which could
potentially interfere with binding to actin phosphorylated at residue Y53. To detect and
immuno-precipitate p85β protein, an antibody with an epitope outside the N-terminal SH2
domain was chosen to prevent potential interference of the antibody with the interaction.
Antibodies specific to endogenous p85α with epitopes outside the N-terminal SH2 domain
were tested as well, but either produced a band at an incorrect size or showed overall low
levels of specificity and or a weak signal (data not shown), which could potentially be due to
low expression levels in this cell type.
I found that FLAG-tagged actin can bind to endogenous p85β in HEK293 cells (Figure
13A) and there is little non-specific binding with cells expressing only the FLAG-epitope from
the empty vector. Binding was to be reduced when Y53A mutant FLAG-actin was used
instead of wild-type actin. This suggests that full-length actin and p85β can interact with
each other in human HEK293 cells, and that the Y53 residue may be involved in binding. In
addition, when immunoprecipitation of endogenous p85β was performed, a similar result
was obtained, with wild-type actin binding to p85β and reduced binding to Y53F mutant actin
(Figure 13B).
However, reduction of binding to FLAG-actin with Y53 mutation was not always
observed to the same extent, which is likely due to the fact that the interaction is relatively
weak and that actin tends to have some capacity to bind to beads non-specifically under the
low stringency conditions required to detect the interaction. Due to the fact that actin can
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polymerize, endogenous actin without the Y53F mutation can co-precipitate in variable
amounts and influence the results. For these reasons, further confirmation of the interaction
between full-length proteins and dependence on the Y53 residue with other methods is
warranted, for example by imaging assays such as FRET or PLA. Alternatively, it is possible
that while the Y53 residue of actin appears to be important for the interaction, other parts of
the proteins may contribute as well. Potential candidates for this would be other
phosphorylation sites on actin or other domains on p85β, such as the SH3 domain.
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Figure 13. Co-immunoprecipitation of FLAG-tagged actin and endogenous p85β. (A)
HEK293 cells were transfected with constructs for FLAG vector (V) or FLAG-tagged β-actin
either wildtype (WT) or with a Y53A mutation, and pretreated with 1 mM orthovanadate for
30 min before lysis. IP was performed with a FLAG antibody, and eluate and input were
resolved by SDS-PAGE. Western blots probed with anti-actin and anti-p85β antibodies are
shown. (B) HEK293 cells were transfected with FLAG vector (V) or FLAG-tagged β-actin
either wildtype (WT) or with a Y53F mutation. IP was performed with anti-p85β antibody and
eluate and input were resolved by SDS-PAGE. Western blots probed with anti-FLAG and
anti-p85β antibodies (short and long exposure) are shown.
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Analysis of the interaction between VAV2 and actin in HEK293 cells
To investigate whether actin and VAV2 can interact in human cells, immunoprecipitation
from HEK293 cells was performed in a similar manner as for p85β. HA-tagged VAV2 was
co-expressed in the cells together with FLAG-tagged β-actin and immunoprecipitation was
carried out using antibodies for either FLAG or HA epitopes versus a mouse IgG1 isotype
control for FLAG immunoprecipitation or a rabbit IgG isotype control for HA
immunoprecipitation. Both immunoprecipitations showed that HA-tagged VAV2 can bind to
FLAG-tagged β-actin in HEK293 cells, while there was no or very little binding with the
isotype controls (Figure 14A, 14B). Compared to the input, it appears that only a small
fraction of each protein interacts with the respective other protein, which is to be expected.
First, only a fraction of actin is likely phosphorylated at any one time and second, VAV2 is
known to have other interaction partners as well that can bind to the SH2 domain, such as
ARAP3 (Wu et al. 2012), which could compete with the interaction between actin and VAV2.
I also generated a mutant HA-tagged VAV2 construct that lacks the SH2 domain and
performed immunoprecipitation with FLAG-tagged β-actin. While binding is reduced with the
ΔSH2 construct, residual binding remains (Figure 14C). This suggests either that binding is
somewhat non-specific or that other parts of the VAV2 protein may be involved in the
interaction with actin as well, for example the SH3 domain of VAV2.
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Figure 14. Co-immunoprecipitation of FLAG-tagged actin and HA-tagged VAV2. (A)
HEK293 cells were transfected with constructs for FLAG-tagged β-actin and HA-tagged
VAV2, and pretreated with 1 mM orthovanadate for 30 min before lysis. IP was performed
with a FLAG antibody or mouse IgG1 isotype control and eluate and input were resolved by
SDS-PAGE. Western blots were first probed with anti-FLAG and anti-VAV2 antibodies (left),
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followed by reprobing with anti-HA and anti-actin antibodies (right). (B) HEK293 cells were
transfected with constructs for FLAG-tagged β-actin and HA-tagged VAV2, and pretreated
with 1 mM orthovanadate for 30 min before lysis. IP was performed with an HA antibody or
rabbit IgG isotype control and eluate and input were resolved by SDS-PAGE. Western blots
were first probed with anti-HA and anti-FLAG antibodies (left), followed by reprobing with
anti-VAV2 and anti-actin antibodies (right). (C) HEK293 cells were either untransfected or
transfected with constructs for FLAG-tagged β-actin, and also co-transfected with either HAtagged VAV2 or HA-tagged VAV2 lacking the SH2 domain (ΔSH2). IP was performed with a
FLAG antibody and eluate and input were resolved by SDS-PAGE. Western blots probed
with anti-FLAG and anti-VAV2 antibodies are shown.
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Part Four: Functional characterization of a β-actin Y53F mutant HeLa cell line

Generation of a HeLa cell line with Y53F mutation in β-actin
In addition to studying the interactions between actin pY53 and p85 or VAV2,
respectively, on a biochemical level, I wanted to determine the cellular role of actin Y53
phosphorylation in human cells. One option to begin answering this question is to
investigate changes upon removal of the phosphorylation site, without disturbing protein
structure, expression level or adding a protein tag that could interfere with protein function.
To this end, I generated a knock-in cell line with a Y53F mutation in β-actin, as
phenylalanine cannot be phosphorylated like tyrosine, but is similar in amino acid structure. I
decided to generate the β-actin mutation in HeLa cervical cancer cells, which is a commonly
used cell line that is responsive to extracellular stimuli like growth factors. Moreover, actin
pY53 has been identified in this cell line by mass spectrometry (Sharma et al. 2014) and the
cells appear to primarily express ACTB and ACTG1, but have low expression levels of other
actin isoforms, according to the Cell Atlas database (Thul et al. 2017), which should reduce
potential issues with functional compensation.
As a relatively new gene editing technique, ‘prime editing’ is CRISPR/Cas9-based and
has several advantages over other editing techniques (Anzalone et al. 2019), such as higher
editing efficiency, lower off-target rates and ease of use. The prime editor PE2 consists of a
Cas9 (H840A) nickase enzyme to create a single strand break in genomic DNA, and is
fused to a reverse transcriptase (RT) (Anzalone et al. 2019). By providing a short template
containing the desired edit together with the guide RNA (termed prime editing guide, or
pegRNA), one can generate insertions, deletions and point mutations, as the repair template
generated by the RT is incorporated into the DNA when the nick is repaired (Anzalone et al.
2019). Editing efficiency can be further improved by generating a second nick on the
opposite strand around 50 base pairs upstream or downstream of the intended edit site to
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increase probability of the cell using the provided repair template while preventing doublestrand breaks (Anzalone et al. 2019).
I began by testing three sets of pegRNAs and three sgRNAs for the second nick (Table
5, Appendix) in HEK293 cells, as a proof of concept. Using a restriction enzyme-based
genotyping assay on PCR fragments, I found that two combinations of pegRNA and
sgRNAs gave the highest editing efficiency in polyclonal cell pools (pegRNA1 combined with
sgRNA1, Figure 15A; as well as pegRNA2 combined with sgRNA1, not shown). Very little to
no editing was observed with only the pegRNA but no sgRNA for the second nick, as well as
when no guide RNAs but only the Cas9 (PE2) enzyme were transfected (Figure 15A).
After validation of the assay in HeLa cells, and selection of the best guide RNA
combinations (Table 5), I screened approximately 200 single cell-derived clones for
presence of the mutant allele. Clones were selected for further testing by Sanger
sequencing if the genotyping assay showed at least equally strong bands for the WT and
Y53F mutant alleles. As HeLa cells are not euploid and can have higher than normal
numbers of chromosome 7 (Landry et al. 2013), where the ACTB gene is located (Ng et al.
1985), partially mutated cell clones were frequently observed. Moreover, the assay revealed
that several mutated cell lines contained insertions or deletions as they had additional bands
of different sizes in the genotyping assay.
For these reasons, only one cell clone was obtained that did not have any additional
bands in the genotyping assay and only the mutant, but not the wildtype band size (Figure
15B). This cell clone was expanded for further use and also screened by Sanger
sequencing to confirm the correct mutation (Figure 15C) as well as screen for potential offtarget effects in other actin genes (ACTA1, ACTC1, ACTG1, ACTG2), which showed that
they retained the wildtype sequence (data not shown), as expected.

66

67

Figure 15. Generation of a β-actin Y53F mutant HeLa cell line. (A) Prime editing test in
HEK293 cells with different pegRNA and sgRNA combinations (left) or pegRNAs only. PE2
only refers to the PE2 prime editor without any guide RNAs. Digestion of the PCR product
with the mutation-sensitive enzyme HpyAV yields a distinctive band pattern when TTC (Phe)
instead of TAT (Tyr) codon is present. (B) HpyAV genotyping assay in HeLa cells, where #1
denotes the cell clone that was selected for all further assays as no WT band is present. For
comparison, no efficient editing can be seen for clones #2, #3 and #4. (C) Sanger
sequencing results of a part of the ACTB locus for parental HeLa and Y53F mutant HeLa
cells. Note that the parental cells have a TAT (Tyr) codon, while the mutant cells uniformly
display TTC (Phe) codon.
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Actin Y53F cells display altered protein expression and activation of signaling
pathway components
Based on my findings connecting actin pY53 and p85 proteins, I hypothesized that the
interaction between actin and p85 may serve to regulate PI3K activity, and, as a
consequence, have downstream effects on the PI3K signaling pathway. Therefore, I
investigated whether the β-actin Y53F mutant cells have different levels activation of PI3K
pathway components in response to stimulation. AKT becomes phosphorylated on two key
sites, T308 and S473, by PDK1 and mTORC2/Rictor, respectively, when it is recruited to the
plasma membrane at sites of PIP3 production (Bilanges, Posor, and Vanhaesebroeck 2019).
AKT phosphorylation levels are commonly used as a readout for PI3K signaling pathway
activation, although AKT is not necessary for all PI3K signaling outputs (Bilanges, Posor,
and Vanhaesebroeck 2019).
To compare AKT phosphorylation levels, I performed western blots with antibodies
against AKT pS473 after serum starvation and treatment of the cells with insulin. Insulin is a
well-studied ligand of RTKs (insulin and IGF receptors) (Taniguchi, Emanuelli, and Kahn
2006), and generated a higher level of activation compared to EGF at the concentrations I
tested in this cell line. As a control, to determine whether the changes in AKT
phosphorylation levels were dependent on PI3K activity, I used the cell-permeable PI3K
inhibitor Wortmannin (Ui et al. 1995).
I found that AKT phosphorylation at S473 was higher in actin Y53F mutant versus
parental cells in the insulin treated condition, relative to total AKT protein levels (Figure 16).
Basal AKT phosphorylation levels in serum-starved cells were very low in both parental and
Y53F cells and levels were strongly decreased when cells were pre-treated with Wortmannin
prior to insulin stimulation.
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Figure 16. Y53F mutant cells show higher AKT phosphorylation upon insulin
treatment. HeLa cells were serum starved for 24 h followed by insulin treatment (15 min,
250 nM), or pre-treated with Wortmannin (15 min, 500 nM) followed by addition of insulin.
Cell lysates were resolved by SDS-PAGE and western blots were carried out with AKT
pS473 antibody, followed by reprobing with AKT and tubulin antibodies as loading controls.
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Cell signaling in general, and response to starvation and insulin stimulation in particular,
are complex processes that involve multiple feedback loops and regulatory mechanisms
(Taniguchi, Emanuelli, and Kahn 2006). Therefore, to gain a better understanding of the
broader effect of the actin Y53F mutation on signaling pathway activation, as well as to
determine changes in protein expression and modification sites independent of insulin
treatment, I performed insulin stimulation in parental and actin Y53F cells for analysis by
reverse phase protein array (RPPA), which was performed by the Functional Proteomics
core facility at MD Anderson Cancer Center. This technique uses several hundred highly
validated antibodies to measure protein levels and selected post-translational modifications
in parallel in different cell lysates. For a detailed description of the RPPA process see
Chapter IV: Materials and Methods.

The RPPA results yielded several differences in protein levels and phosphorylation sites
in the parental HeLa versus actin Y53F mutant cells independent of insulin treatment (Figure
17A). Among the most strongly down-regulated proteins in the mutant cells, independent of
insulin stimulation, were fibronectin, EMA, RAD51, and DVL3. Fibronectin is an extracellular
matrix protein with a role in cell signaling (Pankov and Yamada 2002) and intracellular
fibronectin has been shown to interact with actin in an AP-MS study (Humphries et al. 2009).
EMA (MUC1) is a cell surface glycoprotein involved in cell adhesion and overexpression is
correlated with increased PI3K/AKT pathway activity in rat fibroblasts (Raina, Kharbanda,
and Kufe 2004). RAD51 is a protein involved in DNA damage repair (Laurini et al. 2020).
DVL3 is a protein in the Wnt signaling pathway and important for cell polarity and
cytoskeletal structure that can localize to the actin cytoskeleton through an actin binding site
and DVL3 knockdown causes a decrease in filamentous actin levels (Capelluto et al. 2002;
Li et al. 2019).
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Figure 17. Y53F mutant cells show differences in protein expression and PTMs in
RPPA. (A) Volcano plot of upregulated (red) and downregulated (blue) proteins and PTMs
in β-actin Y53F mutant versus parental cells independent of insulin treatment. The horizontal
dotted line denotes an FDR of 0.05 (linear regression model). (B) Volcano plot of analysis of
proteins and PTMs for which insulin treatment changes the differences between parental
and Y53F mutant cells. For example, DAPK1 pS308 is lower in Y53F mutant than parental
in the untreated condition, but higher than parental after insulin treatment (red), whereas
ATRX is higher than parental in the untreated cells, but lower than parental after insulin
treatment (blue). The horizontal dotted line denotes a p-value of 0.05 (rank-sum test). RPPA
data were generated by the Functional Proteomics Core Facility (MD Anderson Cancer
Center).
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Among the most strongly up-regulated proteins (Figure 17A) in the mutant cells
independent of insulin treatment were PDCD4 (programmed cell death protein 4), proteins
involved in cell metabolism such as FASN, PHGDH and G6PD, as well as the glucocorticoid
receptor NR3C1. PDCD4 is a translation inhibitor and has increased levels in serumdeprived cells. Upon addition of serum to cultured cells, it is phosphorylated in a PI3K and
mTOR-dependent manner by S6K1 and degraded (Dorrello et al. 2006). Another protein
with higher levels in the mutant cells is PHGDH, an enzyme involved in serine biosynthesis,
that is frequently upregulated in cancer and important for cell proliferation (Li and Ye 2020;
Ma et al. 2013). Another notable upregulated protein is Glucose-6-phosphate
dehydrogenase (G6PD). This enzyme catalyzes the first step of the pentose phosphate
pathway and produces NADPH, an important mediator for maintaining cellular ROS levels
and metabolic pathways and G6PD is frequently upregulated in cancer and involved in cell
proliferation and migration (Zhang et al. 2014).
Interestingly, phosphorylation of NDRG1 at T346 as well as p90RSK at T573 were
significantly higher in the actin Y53F mutant compared to the parental cells (Figure 17A),
whereby the increase of NDRG1 phosphorylation was stronger upon insulin treatment
(Figure 18D). NDRG1 is a signaling protein responsive to stress signals and it is
phosphorylated on several sites by SGK1, GSK-3 and also AKT (Sommer et al. 2013).
Intriguingly, NDRG1 is also known to be phosphorylated upon insulin treatment, and
phosphorylation is abolished when the cells are treated with a PI3K inhibitor (Inglis et al.
2009). p90RSK is a kinase in the MAPK pathway and is involved in regulating proliferation
and survival (Dalby et al. 1998; Romeo, Zhang, and Roux 2012). Among the downregulated
proteins in the mutant cells independent of insulin treatment is DUSP4, a dual-specificity
phosphatase for ERK1/2 in the MAPK pathway and part of a negative feedback loop for
EGFR signaling (Chitale et al. 2009). Decrease in DUSP4 expression levels occurs cancer
due to loss of the genomic locus or epigenetic silencing, which leads to increased ERK1/2
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activity, cell proliferation and a diminished response to chemotherapy (Ichimanda et al.
2018; Balko et al. 2012). I validated the RPPA results for DUSP4, DVL3 and phosphorylated
NDRG1 by western blot, which shows that that the results are largely consistent (Figure
18A, 18B, 18C).

Another type of analysis was performed to investigate for which protein levels or
modification sites treatment with insulin changes the differences between parental and Y53F
mutant cells (Figure 17B). Interestingly, using this analysis, there are several proteins or
modifications with an increase in response to insulin in the mutant cells, despite lower or
equal levels in the untreated condition. This suggests that for these proteins, the increase
with insulin is stronger in the Y53F mutant cells (for example for RRM2), or that insulin
weakens baseline differences in protein expression or modification (for example for Merlin,
Stat3, Myosin IIa pS1943).

Activation of canonical PI3K/AKT components was observed in response to insulin
stimulation, most strongly for phosphorylation of p70 S6K (T389) and S6 (S235, S236,
S240, S244). However, there was no significant difference between parental and Y53F
mutant cells. Slightly higher activation in the mutant versus parental cells or at least a (not
significant) trend in this direction was found for phosphorylation of TSC2 (pT1482), 4E-BP1
(pT37/pT46), as well as the mTORC2 protein RICTOR (pT1135), which is responsible for
AKT phosphorylation at S473 (Sarbassov et al. 2005).
AKT phosphorylation (pS473) was increased in response to insulin as well, however, the
activation was relatively weak and there was no stronger activation in the actin Y53F mutant
compared to the parental cells, and no significant increase for either parental or Y53F cells
was found for AKT pT308 phosphorylation in response to insulin. This result, which is
different from what I found by western blot, is likely due to technical reasons, as longer
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sample processing times for RPPA than western blot could lead to distinct signaling
pathway components being most active. In fact, for the RPPA validation experiments by
western blot (Figure 18), samples were processed analogous to RPPA, and I was unable to
detect an increase in either parental or Y53F cells in AKT phosphorylation levels after insulin
stimulation (data not shown). Therefore, the differences are likely due to different sample
processing, or the fact that serum starvation before insulin treatment was performed for 24 h
for the pAKT western blot assay and only 18 h for the RPPA and western blot validation
experiments. Differential sensitivities of both assays for small differences in phosphorylation
levels could also account for the observed inconsistencies.
Overall, the RPPA results show that several proteins and signaling pathway components
are differentially regulated in the HeLa parental versus actin Y53F mutant cells, suggesting
that the β-actin Y53F mutation, and, by extension, potentially β-actin Y53 phosphorylation,
plays a role in cell biology. However, further validation of the findings by complementary
assays and rescue experiments is required to ascertain that these changes are indeed
caused by absence of β-actin Y53 phosphorylation, and not off-target effects from gene
editing or clonal effects due to single cell clone isolation. Moreover, it will be important to
distinguish direct versus indirect effects of the mutation, and to test whether these changes
are dependent on the interaction between actin and p85 or VAV2 (see Chapter III:
Discussion).
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Figure 18. Validation of select proteins and PTMs from RPPA. Parental and β-actin
Y53F cells were serum-starved for 18 h followed by insulin treatment or no treatment
(control). Equal amounts of cell lysates were resolved by SDS-PAGE and probed with the
respective antibodies, followed by reprobing with α-tubulin. (A) Western blot using an
antibody for DUSP4. (B) Western blot using an antibody for NDRG1 pT346. (C) Western
blot using an antibody for DVL3. (D) Plot of linear protein or phosphorylation levels from
RPPA for DUSP4, NDRG1 pT346 and DVL3 for comparison. Note that samples used for
RPPA are not the same as western blot samples, but prepared in a similar manner.
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Actin Y53F cells have an altered gene expression profile
Given that the β-actin Y53F mutant cells appeared to have differential activation of some
PI3K pathway components based on western blot and RPPA data, and that PI3K/AKT
pathway activation can indirectly affect gene expression, for example by regulating
transcription factors (Hoxhaj and Manning 2020), we decided to perform an mRNA
sequencing experiment to measure differences in gene expression. Parental HeLa and βactin Y53F cells were either serum starved (untreated control) or serum starved and treated
with insulin at two different timepoints (2 hours and 6 hours) to assess both baseline and
insulin-dependent gene expression changes. Library preparation and sequencing was
performed by the MD Anderson Science Park Next Generation Sequencing Core facility
(Director: Dr. Jianjun Shen) and bioinformatics analysis was carried out by Dr. Bin Liu.
In total, we found 7931 genes differentially expressed between parental and Y53F
mutant cells in the untreated condition, and 8138 and 8321 differentially expressed genes
after 2 hours and 6 hours of insulin treatment, respectively. With a Log2 fold change cut-off
of ± 1.0, there were 239 genes significantly upregulated and 1093 genes downregulated in
Y53F vs. parental cells in the untreated condition (Figure 19A), 295 up- and 1060
downregulated genes after 2 hours, and 435 up- and 966 downregulated genes after 6
hours of insulin treatment (Figure 28). In the parental cells only, insulin treatment for 6 hours
increased expression of 113 and decreased expression of 139 genes compared to the
untreated control, whereas in the Y53F mutant cells, there were 445 up- and 192
downregulated genes after 6 hours of insulin treatment compared to untreated cells (Figure
28).
Principal component analysis (PCA) shows that 86 % of the variance in gene expression
can be attributed to the Y53F mutant vs. parental cell line, and only 8 % of the variance is
due to insulin treatment (Figure 19B), indicating that the mutation status has a stronger
effect on gene expression than insulin treatment. Overall, the three technical replicates for
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each condition are clustered very closely together, as expected, and 6 hours of insulin
treatment produces stronger changes compared to the untreated control than 2 hours of
insulin treatment.
When comparing which genes have increased or decreased expression levels, there is a
large overlap between genes independent of insulin treatment. Among the upregulated
genes (Log2 fold change ± 1.0), 158 genes (~ 28 %) are shared between all three
conditions, whereas 211 genes (~ 38 %) are upregulated in the Y53F mutant vs. parental
cells only after 6 hours of insulin treatment (Figure 19C). Among the genes downregulated
in Y53F mutant over parental cells (Log2 fold change ± 1.0), the overlap is larger with 658
genes (~ 44 %) shared between all three conditions (Figure 19D). Similar patterns are
observed with a Log2 fold change of ± 2.0 (not shown).
Of note, more genes are upregulated in response to insulin the Y53F mutant cells
compared to the parental cells. Among the upregulated genes at 6 hours vs. the untreated
cells, the majority (88 genes, ~ 78 %; Log2 fold change ± 1.0) of those increased in the
parental cells are also increased in the mutant cells, but there are 357 genes increased in
the mutant, but not in the parental cells (Figure 19E). This suggests that the mutant cells
upregulate largely the same set of genes in response to insulin as the parental cells, but
have increased expression of an additional set of genes after insulin treatment. Interestingly,
this set includes many genes related to metabolic processes.
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Figure 19. Y53F mutant cells have a different gene expression profile. (A) Differentially
expressed genes in Y53F mutant vs. parental untreated cells. Upregulated genes (red) and
downregulated genes (blue) in the Y53F vs. parental with a Log2 fold change cut-off of ± 1.0.
(B) Principal component analysis (PCA) of all three technical replicates for each condition.
WT refers to parental cell line, Y53F refers to mutant cell line. (C) Venn diagram of
upregulated genes in Y53F versus parental cells with a Log2 fold change cut-off of ± 1.0. (D)
Venn diagram of downregulated genes in Y53F versus parental cells with a Log2 fold
change cut-off of ± 1.0. (E) Venn diagram of upregulated genes after 6 hours of insulin
treatment versus untreated cells, in parental and Y53F mutant cells with a Log2 fold change
cut-off of ± 1.0. Figures for Panels A and B were generated by Dr. Bin Liu (MD Anderson
Cancer Center), and Venn diagrams in Panels C, D and E were generated using the
BioVenn web tool (Hulsen, de Vlieg, and Alkema 2008).
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Using the DAVID bioinformatics database (Huang da, Sherman, and Lempicki 2009b,
2009a), I performed pathway analysis (KEGG pathways) of the differentially expressed
genes (Log2 fold change ± 1.0) to determine whether any gene sets and pathways are
increased or decreased in the Y53F mutant cells compared to the parental cells.
Interestingly, in the untreated condition, the downregulated genes in the mutant cells belong
to pathways related to focal adhesions, interactions between extracellular matrix and
receptors, as well as several signaling pathways such as Ras and PI3K/AKT signaling
pathways, and regulation of the actin cytoskeleton (Figure 20A). The upregulated genes
show enrichment of only a few pathways, such as Renin secretion.
After 6 hours of insulin treatment, the downregulated genes in the Y53F mutant cells
over parental cells are largely enriched in similar pathways as in the untreated condition,
such as focal adhesion, extracellular matrix interactions, the PI3K/AKT pathway and
regulation of the actin cytoskeleton (Figure 20B), suggesting that, with regard to pathways,
insulin treatment does not strongly change the pattern. There are a few more significantly
enriched pathways for the upregulated genes and they include, for example, biosynthesis of
steroid hormones.
Given my interest in the involvement of the actin Y53F mutation in PI3K signaling, I
analyzed the genes belonging to the PI3K/AKT pathway more closely. Strikingly, they do not
include genes for downstream components in the pathway (downstream of PI3K enzyme),
but rather upstream components, receptors and extracellular factors, such as collagen,
fibronectin, many integrins, growth factor receptors, and growth factors (IGF1, FGF12,
PDGFB), and this general pattern appears to be independent of insulin treatment. Moreover,
while not part of the pathway analysis due to a smaller fold change, both the insulin receptor
and IGF1 receptor are downregulated in the mutant cells as well.
The downregulated genes associated with actin cytoskeleton regulation are partially
overlapping with those in the PI3K/AKT pathway, for example integrins, FGF genes and
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PDGFB, but there are some genes encoding cytoskeletal regulators as well, such as LIMK1,
MYLK and WAS, as well as a few involved in Rho GTPase signaling, for example RAC2 and
PAK6.
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Figure 20. Pathway analysis of differentially expressed genes in Y53F mutant versus
parental cells. Genes that are up- and downregulated in the Y53F mutant versus parental
cells in untreated cells (A) or after 6 hours insulin treatment (B) with a Log2 fold change cutoff of ± 1.0 were used for pathway analysis with DAVID, and up to 15 KEGG pathways that
are most significantly enriched among the upregulated genes (red) or the downregulated
genes (blue) are displayed. The vertical dotted line indicates a p-value of 0.05. Red labels
are used to highlight pathways of particular interest.

Next, I compared the differentially expressed genes with the RPPA results. Given that
insulin treatment for the experiments was performed for a different length of time to account
for the expected faster dynamics of phosphorylation changes compared to gene expression
changes, I only analyzed the overlap between untreated (serum-starved) genes and
proteins. Among the significantly upregulated genes or proteins (irrespective of whether a
PTM-specific antibody was used for RPPA or not), there was a 45 % overlap (35 out of 78
proteins). Strikingly, when only those proteins were considered for which a Log2 fold change
of at least 0.3 was measured in RPPA, 8 out of 10 were also found to be increased on the
RNA level. For the downregulated genes and proteins, the overlap was somewhat smaller,
with a 40 % overlap (28 out of 70) without a fold change threshold and a 52 % overlap (11
out of 21) when only those proteins with a Log2 fold change of > 0.3 were considered.
Nevertheless, these results suggest that both methods produce comparable results, albeit
with different depth, and that many of the changes I observed likely occur on the
transcriptional and not the protein level, for example the decreased levels of fibronectin and
DUSP4. However, there are a few exceptions, for example for DVL3, which was found to be
decreased in the Y53F mutant in RPPA, but not in RNA sequencing.
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Actin Y53F cells do not show a difference in cell proliferation
In addition to analyzing protein level and gene expression changes in the β-actin Y53F
mutant cells, I also performed assays to test whether introducing the mutation has any effect
on cell proliferation. I found that there is no significant difference in proliferation between
parental and Y53F mutant cells using a crystal violet assay over a time of four days (Figure
21). While there appeared to be slight trend toward slower proliferation of the mutant cells,
this difference was not statistically significant (p = 0.0979), indicating that the β-actin Y53F
mutation does not affect cell proliferation enough to detect a difference with this assay.

Figure 21. β-actin Y53F mutation does not affect cell proliferation. Parental and Y53F
cells were seeded in parallel in four 12-well plates (one for each day) and cell proliferation
was assessed with a crystal violet assay. The graph represents the mean of three
independent experiments (displayed as mean with SD). There was no significant difference
between parental and Y53F cells (two-way ANOVA; p = 0.0979).
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Actin Y53F cells have a migration defect
PI3K signaling is not only one of the major signaling pathways regulating cell growth,
and proliferation, but is also important for cell motility and migration, as PI3Ks are involved in
several aspects of the migration process including cell protrusion, polarity and cell adhesion
(Cain and Ridley 2009). Moreover, actin filament dynamics are a key element of cell motility
that is tightly regulated by various actin-binding proteins (Pollard 2016). Therefore, it is
conceivable that introducing the actin Y53F mutation may have an effect on cell migration,
either through affecting the interaction with p85 and PI3K, by regulating actin polymerization,
or both. To test whether the actin Y53F mutant cells show differences in cell migration, I
performed monolayer wound healing assays with the cells in collagen-coated culture dishes.
I found that the actin Y53F mutant cells close the gap more slowly than the parental
HeLa cells (Figure 22A, 22B). This difference is partially alleviated when the migration assay
is performed in the presence of insulin, which stimulates migration, and with insulin, actin
Y53F mutant cells migrate almost as fast as the parental cells (Figure 22A, 22B).
To test whether the increase in migration speed is dependent on PI3K activity, I also
performed the assay in the presence of the pan-PI3K inhibitor Wortmannin. However, no
difference was observed between cells treated with Wortmannin and insulin versus insulin
only (data not shown). This result could either indicate that increased migration upon insulin
addition is not dependent of PI3K activity or that the inhibitor is not effective enough
throughout the assay duration (48 h) to affect migration. In fact, Wortmannin is less stable in
culture medium than water due to reactions with certain amino acids (Yuan et al. 2007);
however, further investigation is required to determine if this plays a role in this case.
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Figure 22. β-actin Y53F mutant cells migrate slower than parental cells. (A)
Representative images of migration assays that were performed with parental and Y53F
mutant cells either in the absence or presence of insulin (250 nM). Vertical white lines
indicate the approximate width of the gap for better visualization but not exact measurement
purposes. (B) Quantification of migration assays. The graph represents the mean of three
replicate experiments and differences were calculated between Y53F and parental cells.
Untreated: p = 0.0365 (two-way ANOVA) and with insulin: p = 0.2949 (two-way ANOVA).
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Part Five: Analysis of mechanisms regulating actin Y53 phosphorylation

Attempted generation of actin pY53-specific antibodies
Even though actin Y53 phosphorylation has been frequently identified by mass
spectrometry in various cell lines and tissues, we aimed to study this modification in our cell
system using a specific antibody. Such a tool would allow to investigate not only the level of
actin pY53 in various conditions and cell types, but also help to study its regulation as well
as the subcellular localization of the modified actin and potential colocalization with its
‘reader’ proteins. There are a few commercial sources for antibodies raised against pY53
actin peptides, and we also had custom antibodies raised against this modification from
different sources.
First, to test whether the antibodies are specific to only the phosphorylated actin peptide
but not the unphosphorylated peptide, I performed peptide dot blots. To this end, the peptide
is spotted on nitrocellulose or PVDF membranes and probed with the antibody in question. I
found that the actin pY53 antibodies I tested showed high specificity for only the modified
peptide and no or very little signal for the unphosphorylated one (Figure 23A).
Next, I performed western blotting with the antibodies as well as immunoprecipitation of
FLAG-tagged actin (either wildtype or Y53F mutant) on lysates from HEK293 cells to enrich
actin and test the specificity of the antibodies. Given that the antibodies should be specific
for actin phosphorylated at the Y53 residue, the signal should be strongly reduced in
immunoprecipitation of the Y53F mutant FLAG-actin. However, I found that while the
antibodies do recognize a weak band the size of actin in whole cell lysates as well as a band
at the correct size for FLAG-actin in the immunoprecipitation, no detectable reduction was
observed with the Y53F actin compared to wildtype. An example of one of the antibodies
produced by Biomatik is shown in Figure 23B. This suggests that either the antibodies are
not able to specifically recognize the phosphorylated actin and/or that the levels of
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phosphorylation in the cell lysates are very low under the tested condition and therefore the
band may only reflect background signal.

Figure 23. Attempted validation of actin pY53 antibodies. (A) Peptide dot blot results for
antibodies produced by Biomatik. Results for antibodies from two different rabbits are
shown. (B) HEK293 cells were transiently transfected with either empty FLAG-vector (V),
FLAG WT β-actin (WT) or FLAG Y53F β-actin, pretreated with 1 mM orthovanadate for 30
minutes and lysed. Equal amounts of lysate were used for immunoprecipitation with antiFLAG beads and bound proteins eluted after IP. Input and IP elutions were probed with
actin pY53 (Biomatik RB1787) antibodies, followed by reprobing with pan-actin antibody.
Arrowheads indicate the approximate size of FLAG-tagged actin.
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Identification of potential actin Y53 kinase candidates
Little is known about the enzymatic regulation of actin PTMs, and tyrosine
phosphorylation in particular, by dedicated kinases and phosphatases. We reasoned that
knowing the kinase(s) responsible for phosphorylating actin at Y53 could help to better
understand its regulation and physiological function. Therefore, an in vitro phosphorylation
assay with an unphosphorylated actin Y53 peptide was performed by Reaction Biology
Europe GmbH. This service includes 94 tyrosine kinases or kinase mutants that are
individually incubated with the peptide, and phosphorylation is measured by incorporation of
33

Pi. The results showed that three kinases, AXL, EPHB3, and a MET Y1235D mutant had a

signal at least three-fold higher than the background signal without the peptide (Figure 24A).
However, signals for all three kinases with the actin peptide were relatively low and below a
threshold of five-fold above the background of the assay plate, in particular for the MET
Y1235D mutant kinase.
For a first follow-up investigation, I decided to focus on AXL, as it has been shown to
colocalize with actin (Zajac et al. 2020). I tested whether AXL can directly interact with actin
using anti-FLAG immunoprecipitation from HeLa cells transfected with either the empty
FLAG vector or FLAG-tagged β-actin. I found that endogenous AXL can be
immunoprecipitated by FLAG- tagged β-actin but does not bind in the empty vectortransfected condition, indicating that it may indeed interact with actin in HeLa cells (Figure
24B). It will however be necessary to test whether this interaction is direct or mediated by
other proteins, whether AXL indeed can directly phosphorylate actin in cells, as well as
whether this phosphorylation occurs on the Y53 residue and under what conditions.
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Figure 24. Identification of potential actin Y53 kinase candidates. (A) Partial results of
the in vitro phosphorylation assay (performed by Reaction Biology Europe GmbH). Kinases
with a ≥ 3-fold kinase with peptide/kinase without peptide ratio are highlighted in red. (B) Coimmunoprecipitation results for FLAG-tagged β-actin and endogenous AXL. HeLa cells were
transiently transfected with either empty FLAG-vector (V) or FLAG-β-actin (WT), serum
starved for 5 h followed by treatment with insulin (250 nM) and pervanadate (0.5 mM) for 15
minutes. Equal amounts of lysate were used for immunoprecipitation with anti-FLAG beads.
Input and IP elution were used for western blots and probed with AXL and actin antibodies.
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Chapter III: DISCUSSION
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Overview of the findings and potential model
Post-translational modifications of actin have been known to exist for many decades;
yet, their functional relevance, and mechanisms of action have remained an understudied
area of actin biology (Terman and Kashina 2013; Kashina 2020). Our approach of
deciphering actin PTM functions by identifying PTM ‘reader’ proteins provides a new angle
to study this area in a mechanistic manner. My findings demonstrate that an actin
phosphorylation site on tyrosine 53 (pY53) enables phosphorylation-dependent interactions
with SH2 domains of p85 and VAV2, which provides a link between actin tyrosine
phosphorylation and cell signaling. I explored the binding mechanism between actin pY53
and the SH2-domain containing proteins through biochemical and structural analyses,
revealing that the actin pY53 peptide can bind to the p85 N-terminal SH2 domain with a
partially unique mechanism that is distinct from binding to the canonical motif of p85 SH2
domain ligands (Songyang et al. 1993; Nolte et al. 1996). Moreover, using a human cell line
harboring a Y53F mutation in β-actin to abolish phosphorylation of this site, I performed
functional analyses to dissect the effect of the mutation, and, by extension, potentially of
actin Y53 phosphorylation, particularly in growth factor-stimulated signaling. I found that
several signaling pathway components and phosphorylation sites as well as non-signaling
related proteins are differentially regulated in the Y53F mutant cells, and that many of these
changes in protein levels are correlated with gene expression changes. Lastly, to expand
my study beyond tyrosine phosphorylation ‘readers’, I began searching for the kinase(s)
responsible for actin pY53, and identified two candidate kinases; this provides an interesting
target for future investigation.
While more investigation is required to confirm my findings and fully dissect the roles of
actin pY53, my data support a model in which actin becomes phosphorylated on tyrosine 53,
possibly by a receptor tyrosine kinase, to create a binding site for SH2 domain-containing
proteins such as p85, and thereby regulate signaling pathways and gene expression. This
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provides an interesting new perspective and potential molecular mechanism for actin
functions through its PTMs.
In the following sections, I will discuss my findings in detail, focusing first on the broader
roles of actin tyrosine phosphorylation in cell signaling and then my in vitro investigation of
potential actin pY53 ‘readers’ using biochemical and structural analyses, followed by a
discussion of my functional studies in the β-actin Y53F cell line.

Roles of actin tyrosine phosphorylation in signaling
The idea of actin becoming phosphorylated in response to extracellular stimuli has been
investigated before, albeit only in a relatively small number of studies. Actin tyrosine 53
phosphorylation is a very prominent modification in the amoeba Dictyostelium discoideum
(Howard, Sefton, and Firtel 1993; Liu et al. 2006). The fact that, in this organism, actin
tyrosine phosphorylation is strongly increased in response to stress and spore maturation
but also upon return to nutrient-containing growth medium (Liu et al. 2006), suggests that
this modification is dynamically regulated depending on extracellular conditions like nutrient
availability. This is particularly interesting, as it links actin phosphorylation to signaling
processes, rather than just modulation of the cytoskeleton, which fits well with my findings
connecting actin pY53 with p85 and VAV2 proteins. Given that actin Y53 phosphorylation
impairs polymerization (Liu et al. 2006), it appears possible that phosphorylated actin is
primarily present as monomeric G-actin, rather than as part of actin filaments. This in turn
might enable interactions with phosphorylation ‘reader’ proteins, that could otherwise be
sterically hindered in actin filaments as actin Y53 is directly adjacent to the D-loop of actin in
subdomain 2 that is important for polymerization (Dominguez and Holmes 2011).

Importantly, D. discoideum contains a homolog of the catalytic subunit of PI3K, but it
does not possess direct homologs of the p85 regulatory subunit (Philippon, Brochier94

Armanet, and Perriere 2015) or proteins with similar domain structures to the VAV family of
Rho GEFs (Vlahou and Rivero 2006). However, it does have 12 SH2 domain-containing
proteins (Goldberg et al. 2006), which could potentially recognize actin pY53 and might be
involved in downstream functions. Curiously, one of those SH2 domains is found in a kinase
that is important for chemotaxis and negatively regulates the PI3K pathway (Moniakis et al.
2001).
Alternatively, it is possible that the roles of actin pY53 are distinct, or only partially
overlapping between D. discoideum and animals, or that actin pY53 phosphorylation is an
evolutionary relict that only plays a minor role in animals, unlike in D. discoideum where it is
very important (Jungbluth et al. 1995; Liu et al. 2006). However, the Y53 residue is highly
conserved in eukaryotes and mutation to phenylalanine has occurred only in a few rare
cases; this has been attributed to the fact that this kind of mutation would go along with
losing an important mechanism of regulation (Liu et al. 2010). Moreover, phosphorylation of
actin at Y53 is frequently found by mass spectrometry in human cells (Sharma et al. 2014;
Helou et al. 2013; Rikova et al. 2007), and there is evidence of increased tyrosine
phosphorylation levels of mammalian actin upon insulin and pervanadate treatment
(Machicao, Urumow, and Wieland 1983), and upon induction of long-term potentiation, a
process involving several transmembrane receptors and kinase cascades (Bertling et al.
2016; Molnar 2011).
Taken together, this suggests that actin Y53 phosphorylation may have evolutionarily
conserved functions, and could potentially play important roles in biological processes such
as stress response and cell signaling, processes that both PI3K and VAV2 are involved in.
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In vitro analysis of actin pY53 ‘readers’ reveals interaction mechanisms with common
and unique features
We opted to begin studying the functions of actin PTMs, and actin tyrosine
phosphorylation in particular, through identifying specific interacting proteins, or ‘readers’ for
these modifications, using a protein domain array approach. We decided to focus on the
interactors for an actin pY53 peptide, p85 N-SH2 and VAV2 SH2 domains (Figure 5) as the
main topic of this study; however, we also screened other actin pY peptides on the array
(Figure 25), which revealed that the different actin peptides have unique binding profiles,
likely due to their sequence characteristics. Nonetheless, there are interactions that are
found for more than one peptide. For example, CRK SH2 domain binds to actin pY91 and
pY198 peptides, but not pY53 (Figure 25). However, whether these interactions occur in
cells and are physiologically relevant remains to be determined. The protein domain array
results suggest that either there may be some redundancy between different actin tyrosine
phosphorylation sites to certain SH2 domains, or that some SH2 domains may have lower
levels of substrate specificity. Moreover, phosphorylation of different actin residues might
occur in different contexts and cell types, for example depending on kinase activity and
expression; therefore, interactions with different SH2 domains may also occur in a contextdependent manner (Tinti, Panni, and Cesareni 2017), and further work is needed to dissect
the roles of individual actin tyrosine phosphorylation sites and their binding partners.

In addition to protein domain arrays, phosphotyrosine peptide libraries have been
screened against single SH2 domains to determine which sequence motifs preferentially
bind to which domains; this revealed several interesting characteristics and binding motifs
for SH2 domains (Tinti, Panni, and Cesareni 2017). For example, in an early study,
Songyang and colleagues performed a screen with a p85 N-SH2 domain and found that this
domain generally prefers E, I, M or V at pY+1, and has a strong preference for M at pY+3
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over other amino acids (Songyang et al. 1993). At pY +2, there is no strong preference for
any amino acid, even though a slight increase can be seen for E, G, I, L or F (Songyang et
al. 1993). For this reason, the canonical motif for this domain was determined as pYXXM,
which is present in many receptor tyrosine kinases and adaptor proteins that p85 has been
shown to interact with in cells. We found that the actin pY53 peptide can interact with p85 NSH2 domains despite lacking such a motif (Figure 5, 6, 7). This suggests that either the
preference of the p85 N-SH2 domains for M at pY+3 is not as strong as assumed, or that
the actin sequence around pY53 has other features mediating the interaction despite the
lack of this motif, or that the binding event we have observed is only mediated by the
phospho-tyrosine itself, irrespective of the surrounding sequence. While investigating the
first possibility is beyond the scope of my work, and given that most of the actin
phosphotyrosine peptides we screened appear to have a distinct set of interactions, which
makes the third possibility unlikely, it is probable that the lack of M at pY+3 in the actin pY53
peptide is compensated by additional interactions. Solving crystal structures for both p85α
and p85β N-SH2 domains bound to the actin pY53 peptide allowed us to analyze this
possibility further. Our structures reveal that interactions of the actin peptide are mediated
not only by the phosphotyrosine itself, but also by at least two additional contacts between
residues of the domain with residues both N- and C-terminal of the phosphotyrosine (Figure
8, 10).
Importantly, I found that abolishing these contacts reduces binding to the actin, but not a
PDGFR peptide with the pYXXM motif (Figure 9). In fact, which residues the p85 N-SH2
domain prefers N-terminal of the pY was not determined in the early study (Songyang et al.
1993). This opens the possibility that there may be a preference for example for D at pY-2,
that, together with V at pY+1 and G at pY+2, is sufficient to mediate the interaction with the
actin pY53 peptide. According to a newer, more systematic analysis of SH2 domain
interacting motifs by Dr. Shawn Li’s group with peptide libraries, D at pY-2 showed a positive
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enrichment at least for the p55γ N-SH2 domain, which is closely related to p85α and p85β
(Huang et al. 2008).

Through our ITC experiments, we found that the binding affinity of the actin peptide to
the p85 SH2 domains is approximately in the same (low micromolar) range as other known
peptide-SH2 domain interactions. The KD of actin pY53 peptide binding to p85α N-SH2
domain is lower (~ 5.2 µM) than to p85β N-SH2 domain (~ 1.1 µM), suggesting that the actin
pY53 peptide may preferentially bind to the p85β N-SH2 domain. When we compare the KD
values to published results for the same SH2 domains, we can see that they are in a similar
range. For example, a tyrosine phosphorylated peptide from CD28 containing the pYXXM
motif, has been shown to bind to the p85α N-SH2 domain with a KD of 3.67 µM (Inaba et al.
2017). In contrast, a peptide from PDGFR (pY751) was shown by ITC to bind to the p85α NSH2 domain with higher affinity (KD around 0.5 µM) (Ladbury et al. 1995), whereas another
study found a PDGFR pY751 peptide to have KD of 1.8 µM for the p85 N-SH2 domain
(Piccione et al. 1993).
In summary, our ITC results fit within the expected interaction affinity range for
phosphopeptide-SH2 domain interactions. The affinity of the actin peptide to the p85β NSH2 domain is higher than to p85α, however, the difference is not very large. Importantly,
SH2 domains interact with phosphorylated peptides in a transient manner, which explains
their relatively low affinity to their ligands. In fact, expression of so-called SH2 domain “super
binders” with very high affinity for pY ligands inhibited EGFR signaling (Kaneko et al. 2012),
suggesting that the transient nature of these interactions is critical for dynamic signal
transduction. Moreover, binding specificity in vivo is likely achieved by a combination of the
interaction affinity itself, avidity effects through other binding sites on the proteins, precise
spatiotemporal regulation of the phosphotyrosine-containing ligands, their competitors and
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the SH2 domain, as well as thermodynamic and kinetic characteristics of the interactions
(Marasco and Carlomagno 2020).

Taken together, my findings raise several interesting questions: first, whether there may
be other ligands with a similar motif to actin pY53 that can be phosphorylated and bind to
the p85 N-SH2 domains. Second, whether the partially unique binding mechanism of the
actin peptide to the domain translates do distinct functional outcomes. Third, related to the
second question, whether mutations in the residues of p85 N-SH2 that are important for the
interaction with actin, but not pYXXM motif-containing ligands such as PDGFR or CD28,
could be used for separation-of-function studies to determine the role of the interaction,
complementary to mutating actin Y53.

Due to the prominent role of PI3K in cancer, more work has focused on the roles and
interaction partners of p85 than VAV2 and less is known about VAV2 SH2 domain binding
motifs. However, on a structural level, the SH2 domains of p85 and VAV2 appear to be
more similar to each other than to other SH2 domains (Wu et al. 2012) and belong to the
same subgroup of domains that are characterized the pY+3 residue being important for the
interactions (Huang et al. 2008). Yet, VAV2 does not seem to strongly prefer the same
binding motif as p85 due to a shallower hydrophobic pY+3 pocket. Rather, it prefers V, E or
L at the pY+1 position, which actin pY53 (pY+1 is V) fulfills, as well as a minor enrichment of
D at pY+3 (which is also the case for the actin pY53 peptide) (Huang et al. 2008). Using
ITC, we found that the actin pY53 peptide binds to the VAV2 SH2 domain with a KD of
~ 1.9 µM. Published KD values for this domain range from 0.27 µM for binding to an ARAP3
peptide (Wu et al. 2012), 3.57 µM for binding to an EphA2 peptide (Ge et al. 2020), to 14 µM
for binding to a TXNIP peptide (Liu et al. 2016). This suggests that the interaction we
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identified between actin pY53 and VAV2 SH2 domain fits well within the expected range of
binding affinities.
However, when we solved the crystal structure of the actin pY53 peptide binding to the
domain, we found that only three residues of the peptide appear to interact with the domain,
whereas the other parts of the peptide are either not resolved in the structure at all or do not
form any interactions (Figure 11). This indicates that either the interaction with just three
residues of the actin pY53 peptide is strong enough to mediate the interaction with the SH2
domain, or that the fact that we do not see the other residues of the peptide may represent
an artifact of the crystal structure. Further analysis using different peptide variants and
mutant SH2 domains, or structural analysis in solution using NMR, would be needed to
determine which possibility holds true.

Lastly, regarding our protein domain array results for the other actin phosphorylation
sites, it is important to note that many of the identified binding events align well with both
known motifs for certain SH2 domains, and that the peptides often bind to several domains
from a similar family or classification of binding motifs (Huang et al. 2008). For example, the
actin pY294 peptide binds to SH2 domains of GADS and GRAP, which are part of the 1C
family of SH2 domains (Huang et al. 2008). The actin pY91 peptide binds strongly the SH2
domain of CRK, which is known to prefer a pYXX(L/P) motif (Liu 2017), which the peptide
contains (pY+3 is L).
In summary, the screen of actin phosphotyrosine peptides on SH2 domain arrays
revealed a number of new and interesting potential actin pY ‘readers’. Together with my
interaction analyses through peptide pull-down and our structural analyses, my results
suggest that actin pY53 can bind to the N-SH2 domains of p85 and VAV2 proteins in a
phosphorylation-dependent manner, and that the actin pY53 peptide binds to p85 with a
partially unique mechanism.
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I also set out to investigate whether I could detect the interactions between full-length
actin and p85, as well as VAV2 in the context of a cell lysate. First, I performed peptide pulldown assays with the unmodified and phosphorylated actin Y53 peptides, and I was able to
detect weak but specific binding of full-length p85α and VAV2 to the phosphorylated, but not
the unmodified peptide. I also detected binding by co-immunoprecipitation between fulllength actin and p85β, as well as VAV2, and observed a reduction in binding to p85β when
the Y53 residue of actin was mutated, suggesting that actin may interact with these proteins
in a cell lysate and that the interaction with p85β may be at least partially dependent on the
Y53 residue. Importantly, while the interaction mechanism and dependence on SH2
domains or phosphorylation have not been studied previously, there is evidence for a
potential interaction between actin and p85 in certain cell types: Using immunofluorescence,
actin and p85 have been shown before to colocalize in cell adhesions in NIH3T3 fibroblasts,
and p85β is important for recruitment of Rho GTPases like Cdc42 and Rac (CariagaMartinez et al. 2014). Moreover, actin and p85 colocalize in the cleavage furrow of dividing
mouse embryonic fibroblasts (MEFs) and actin enrichment at this structure is reduced in
p85α-/- MEFs (Garcia et al. 2006). In isolated cytoskeletal fractions from thrombin-stimulated,
but not resting, platelets, p85 and PI3K activity were found to be closely associated with the
actin cytoskeleton, and this association was reduced by treatment with a tyrosine kinase
inhibitor; however, whether this is dependent on tyrosine phosphorylation of actin remained
unclear (Guinebault et al. 1995). In muscle cells, p85 colocalizes with actin, is enriched in
dorsal ruffles in response to insulin treatment, and co-purified with actin in preparations of
vesicles from these cells in an insulin-dependent manner (Khayat et al. 2000). Using
immunoprecipitation, actin was also found in a complex together with Src kinase and p85
(Kim, Lee, et al. 2013) and interacts with p85 in leukemia cells expressing BCR-ABL
(Brehme et al. 2009). Lastly, actin is phosphorylated on serine residues by PAK1 kinase in
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response to stimulation with opioid receptor agonists, and interacts with PAK1, which, at the
same time, can interact with p85 (Papakonstanti and Stournaras 2002).

Given that VAV2 is a protein directly upstream of Rho GTPases, a family of important
regulators of the actin cytoskeleton (Hanna and El-Sibai 2013), it is not surprising to find that
actin and VAV2 exist in similar subcellular localizations in the cell, such as membrane
ruffles, or colocalize, especially in response to signals activating Rho GTPase signaling
(Tamas et al. 2003; Fujikawa et al. 2003). Even though, to my knowledge, there is so far
little to no evidence for a direct interaction between the two proteins, VAV is known to
associate with certain actin-binding proteins, and, in T cells, actin can itself bind to CD3ζ
receptor, which is also important for VAV2 signaling (Fischer et al. 1998; Rozdzial, Malissen,
and Finkel 1995), indicating that the two proteins may at least be part of related protein
complexes.

Taken together, my results align with evidence from the literature that suggests an
association exists between p85 proteins and actin, as well as potentially between actin and
VAV2, especially in response to RTK signaling pathway activation, for example by insulin.
However, most of the evidence from the literature is correlative and does not demonstrate a
direct interaction and could also be explained by close proximity of the proteins or an
indirect interaction through other proteins. Based on my immunoprecipitation results, I
cannot fully exclude this possibility either, as the Y53F or Y53A mutant actin constructs
could also reduce interactions with other proteins that mediate indirect binding, or affect
actin polymerization, which in turn may indirectly affect the amount of p85 or VAV2 detected
in the precipitate. In order to validate these findings, other methods, such as FRET or BiFC
(bi-molecular fluorescence complementation), would provide valuable information, as they
rely on extremely close physical proximity between two proteins well below typical
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colocalization studies with immunofluorescence and can be performed in living cells and not
a cell lysate (Algar et al. 2019; Kerppola 2008; Pratt et al. 2016), and are therefore less
likely to detect indirect or artifactual associations between proteins. In addition, it would be
important to test by immunoprecipitation or other methods whether only actin
phosphorylated at Y53 can interact with p85 and VAV2 directly; however, due to the fact that
I was not able to obtain an antibody specific to this modification (Figure 23), I was unable to
investigate this further. Lastly, actin contains a PXXP motif (residues P109 to P112), which
could potentially enable (additional) interactions with the SH3 domain of VAV2 and/or p85,
or create an avidity effect to strengthen the interactions. Nevertheless, when combined with
my peptide pull-down and structural data, it appears that at least a fraction of actin may
specifically interact with p85, as well as VAV2, through their SH2 domains when it is
phosphorylated on the Y53 residue.

Functional analysis of cells with a β-actin Y53F mutation reveals changes of gene and
protein levels as well as cell behavior
To expand my study beyond the physical association between actin pY53 and its
potential ‘reader’ proteins, I wanted to dissect the functional role of the actin
phosphorylation. To do this, I chose to generate a HeLa cell line model with a Y53F
mutation in β-actin (Figure 15), as this would abolish phosphorylation of this site, while
preserving the structure of the amino acid as closely as possible. Moreover, Y53F mutant
actin from D. discoideum has been shown to polymerize like WT actin in vitro, and can
inhibit DNase and hydrolyze ATP normally as well and the mutant amoebae did not show
any defect in proliferation (Liu et al. 2010). This is consistent with my findings showing no
significant difference in cell proliferation (Figure 21). In contrast, Y53A mutation does affect
actin polymerization and cytoskeletal structure (Liu et al. 2010).
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Using this cell line, I performed several functional assays to investigate differences
between Y53F mutant and parental HeLa cells, especially with regard to PI3K signaling. For
this reason, I first performed an insulin stimulation assay and looked for AKT
phosphorylation levels, as AKT is almost directly downstream of PI3K activity (Cantley
2002). I found that AKT phosphorylation levels appeared to be higher in the Y53F mutant
cells (Figure 16), which might indicate that actin pY53 has an inhibitory effect on PI3K
activity. To validate these findings and also to test whether gene expression, protein levels
or phosphorylation sites are differentially regulated in the Y53F mutant cells, I performed
insulin stimulation assays for RPPA as well as mRNA sequencing analysis and found
several changes in protein and phosphorylation levels as well as an altered gene expression
profile (Figure 17, 18, 19). Interestingly, the RNA-seq experiments revealed that more genes
are downregulated than upregulated in the mutant cells compared to parental cells (Figure
19), which suggests that the mutation may (indirectly) exert a more negative than positive
effect on transcription. However, in response to insulin treatment, more genes are strongly
upregulated in the mutant cells than the parental cells.
The RPPA analysis also showed many significantly up- and downregulated proteins and
phosphorylation sites (Figure 17), and many of the proteins overlap with deregulated genes
found in RNA sequencing.
Surprisingly, pathway analysis with the RNA sequencing data of the genes that are
downregulated in the mutant cells revealed an enrichment of PI3K/AKT pathway
components (Figure 20). Upon closer inspection, downregulated pathway members are
predominantly upstream regulators, such as extracellular components, growth factors and
growth factor receptors, but not components downstream of PI3K, and they remain
decreased irrespective of insulin treatment, at least at the analyzed timepoints of up to 6
hours. This finding at first appears contrary to my western blot results that showed an
increase in AKT phosphorylation upon insulin treatment (Figure 16), which would indicate an
104

increase in PI3K/AKT pathway activity. However, there are several conceivable explanations
for the divergent observations:
First, it is possible that either the gene expression changes of PI3K pathway
components I observed are indirect (for example due to epigenetic mechanisms or
transcription factors) and not related to the observed increase in AKT phosphorylation and
PI3K pathway activity.
Second, it is possible that the decrease in upstream components is due to a negative
feedback loop that serves to downregulate upstream pathway components to counteract
increased activation of the downstream pathway caused by the β-actin Y53F mutation. For
example, expression regulation of different integrins is highly complex and governed both by
upstream signals like TGF-β exposure, Ras and Wnt signaling pathways, as well as various
epigenetic mechanisms and miRNAs (Deb, Sengupta, and Patra 2012; Chen et al. 2018).
Moreover, decreased expression of some components upstream of PI3K does not
necessarily translate into lower overall pathway activity and output, as signaling pathways
are highly interconnected and crosstalk exists for example between PI3K/AKT and MAPK
signaling pathways (Castellano and Downward 2011; Menges and McCance 2008).
Furthermore, many of the downregulated genes have paralogs that could perform similar
functions and not all of the paralogs show the same expression patterns; for example, while
expression of FGF12 and FGF11 growth factors is strongly decreased in the mutant cells,
expression of FGF1 and FGF2 not decreased. Another potentially important fact is that actin
itself can be phosphorylated by AKT (Vandermoere et al. 2007), which could hint at
additional crosstalk of different actin PTMs in signaling pathways and further add to the
complexity of pathway regulation.
Third, another possibility is that the increased phosphorylation of AKT observed by
western blot is only a minor effect that overall does not represent significant activation of
PI3K-dependent functions including gene expression. The RPPA analysis after insulin
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treatment also did not show large fold changes and a significant increase in the Y53F
mutant cells for phosphorylation sites downstream in the PI3K/AKT pathway, even though
there may be a slight, but not significant trend toward higher activation in the mutant cells.
However, as described above, the comparatively low levels of activation could also be due
to technical reasons.
Lastly, as many gene expression changes are also present in serum-starved conditions,
when differential AKT phosphorylation was not observed by western blot or RPPA, it is
possible that the PI3K pathway, and in particular upstream components therof, are less
active in unstimulated cells due to long-term effects of the β-actin Y53F mutation, or that the
decrease in upstream pathway components is due to a stronger response of the mutant
than the parental cells to serum deprivation, rather than representing true baseline
differences. Testing this possibility could be done by measuring expression levels of related
genes, such as integrins and growth factors, in basal tissue culture conditions in the
presence of serum.

A major challenge in reconciling the findings from RPPA and RNA-seq experiments is to
distinguish between effects directly related to the Y53F mutation (or actin pY53
phosphorylation) and those due to indirect effects, or even off-target effects from gene
editing, as well as clonal effects from cell line selection. Ruling out the latter would require
either a rescue experiment by reintroducing β-actin without the Y53F mutation, or at least
generation of more cell line clones to rule out clonal effects. It is also possible that the effect
caused by the lack of Y53 phosphorylation of β-actin is partially masked and could be even
larger because of compensation by other actin isoforms that could function similarly with
regard to Y53 phosphorylation. To test this possibility and potentially generate a stronger
phenotype, it may be useful to generate Y53F knock-in mutations in the other actin isoforms,
at least those that are expressed in HeLa cells. According to my RNA sequencing data, only
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ACTB (β-actin) and ACTG1 (γ-cytoplasmic actin) are expressed at high levels in both
parental and Y53F mutant cells (data not shown), as expected, which makes ACTG1 the
most obvious candidate for potential functional compensation. The smooth-muscle actins
ACTA2 and ACTG2 and cardiac actin ACTC1 are expressed as well, but only at lower levels
(less than 0.5 % of ACTB). Importantly, knockout of β-actin is known to lead to
compensatory upregulation of the expression of other isoforms (Tondeleir et al. 2012). While
there is a small increase in ACTG1 expression (Log2 fold change ~ 0.3) in the mutant cells,
expression of other isoforms is not significantly increased, indicating that introducing the
Y53F mutation does not function in a similar manner to a β-actin knockout, as expected.

In order to compare the cells with the β-actin Y53F mutation and the parental cells more
broadly, I performed cell proliferation and migration assays. In my assay, I did not detect a
significant change in cell proliferation. This indicates that the mutant cell can grow at a
normal rate and the gene expression changes I observed do not affect any of the processes
involved in regulating cell proliferation enough to cause a detectable difference. Importantly,
as the assay I used does not track single cells, but rather measures the total amount of
viable (adherent) cells at the time of cell fixation, it is unable to distinguish between higher
proliferation combined with higher rates of cell death versus equal proliferation and cell
death rates. In the future, it would be interesting to determine whether apoptosis is affected
in the cells, whether they are more or less susceptible to stress, as well as whether
proliferation rates could be differentially affected if the assay were performed in the
presence of a mitotic stimulus.
In the migration assay, I observed a decrease in migration rate for the β-actin Y53F
mutant compared to the parental cells, suggesting that the mutation affects cell migration
through direct or indirect effects. Given that I observed decreased expression of
extracellular matrix proteins, such as fibronectin, in RPPA and RNA sequencing
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experiments, as well as cell adhesion-related genes like integrins, this could provide a
potential explanation for this phenotype, as these proteins are known to play a role in cell
migration (Meyer et al. 2004; Huaman and Ogunwobi 2020; Romberger 1997). The fact that
“ECM-receptor interaction” and “focal adhesion” are among the most enriched pathways for
the strongly downregulated genes in the mutant cells further adds to this observation.
However, when the migration assay is performed in the presence of insulin, the migration
defect is at least partially alleviated, suggesting that insulin activates signaling pathways that
promote more efficient migration. Based on the RNA sequencing results, after 6 hours of
insulin treatment, focal adhesion and ECM-receptor interaction are still among the
downregulated pathways, suggesting that either 6 hours of treatment are not sufficient to
fully rescue the changes causing the phenotype, whereas the migration assay is performed
over the course of 48 hours, or that other mechanisms are responsible for the increase in
migration speed in the mutant cells upon insulin stimulation.
Another possibility that could cause the decrease in migration in the mutant cells is of
course the fact that β-actin itself has been mutated, which could in theory cause structural
defects in the protein and affect actin filament formation. However, as mentioned above, in
D. discoideum, actin Y53F mutation was shown to not affect actin polymerization or ATP
hydrolysis in vitro (Liu et al. 2010). Therefore, it seems unlikely that the same mutation in
human β-actin would have a strong effect on actin polymerization. Nevertheless, actin
depolymerization dynamics were not investigated in the aforementioned study and might be
altered in the Y53F mutant cells.

Taken together, my functional studies with the β-actin Y53F HeLa cell line suggest that
the Y53 residue, and, potentially Y53 phosphorylation, are important for cellular functions.
Assuming that the observed effects are not due to off-target or clonal effects, which will have
to be ruled out in the future, one can envision several possible mechanisms for how the
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Y53F mutation and/or the lack of actin Y53 phosphorylation might cause the alterations in
gene and protein expression and protein modifications. It is, however, important to note that
these mechanisms are not necessarily mutually exclusive:
First, in line to my central hypothesis, the changes in the mutant cell line could be due to
loss of the interaction between actin and p85 and/or VAV2 proteins. For example, it is
possible that the phosphorylated actin normally serves to sequester p85 (or VAV2) in the
cytosol or on actin filaments, to downregulate the activity of PI3K (or Rho GTPases). This
would explain why I observed an increase in AKT phosphorylation in the mutant cells upon
insulin stimulation. A similar mechanism has been demonstrated for phosphorylated IRS-1,
which forms a cytosolic sequestration complex with p85 to mediate PI3K signaling (Luo et
al. 2005). It is also possible that the effects are caused by a combination of p85 and VAV2
effects, or by a larger protein complex containing both proteins as well as actin. In fact, p85
is known to interact with Rac GEFs in proximity to membrane ruffles and upon growth factor
stimulation (Innocenti et al. 2003).
Second, it is possible that some or all of the changes are independent of the interactions
with p85 and/or VAV2, and rather due to actin itself. For example, the Y53F mutation could
lead to a gain of interaction with proteins that cannot bind efficiently to phosphorylated actin,
as is the case for DNase I, or through structural changes in the actin protein caused by the
phosphorylation, which are absent in Y53F actin (Liu et al. 2006; Baek et al. 2008). It is also
possible that the presence or absence of the phosphorylation mark affects protein stability,
subcellular localization, combinatorial modifications on actin, or actin depolymerization
dynamics. The latter option may lead to structural as well as metabolic changes, as
increased depolymerization rates might go along with higher need for energy to maintain
cytoskeletal structures (Kwiatkowski et al. 2018).

109

Kinase candidates hint at a potential connection between actin pY53 and RTK
signaling
Lastly, to expand my study beyond investigating ‘readers’ of actin Y53 phosphorylation
and to learn more about the upstream regulation of this modification, I aimed to investigate
the levels of this modification in cells directly, and search for the kinase(s) that may be
responsible for depositing this modification and control its levels. To address the first
question, I tested commercially available antibodies generated to be specific to actin pY53,
and we also asked a company to generate another set of polyclonal actin pY53 antibodies
(Figure 23). However, while most of the antibodies I tested performed well on a dot blot with
the modified or unmodified actin peptides, and were also able to recognize both
endogenous or FLAG-tagged actin in a western blot, none of the antibodies were able to
discriminate between wildtype and Y53F mutant actin sufficiently well, suggesting that the
antibodies are not very specific to the phosphorylated form of actin and/or that the levels of
this modification in my cell lysate are too low to be detected by the antibodies and the
remaining signal only stems from a background of unphosphorylated actin. A third possibility
is that the antibodies can cross-react with other phosphorylation sites on actin; however, in a
preliminary experiment with FLAG-tagged actin in which four of the most frequently identified
phosphorylation sites, including Y53, are mutated to phenylalanine, the signal from the
antibody is not strongly reduced (data not shown). For this reason, I was unable to perform
any experiments with the available antibodies. I also tested pan-phosphotyrosine antibodies
(pY-100 and PYK), and while both reacted with immunoprecipitated FLAG-tagged actin,
they did not show a reduction in signal with Y53F mutant actin (data not shown), which
might be due to other phosphorylation sites on actin. An alternative and more specific
method to detect whether actin pY53 phosphorylation levels are altered in response to
certain treatments or in certain cell types would be mass spectrometry.

110

To address the second question, which kinase may be responsible for phosphorylating
actin on the Y53 residue, an in vitro phosphorylation assay on an actin Y53 peptide was
performed with 94 different tyrosine kinases (or relevant kinase mutants). While overall the
signal for all tested kinases with the peptide was relatively low, three receptor tyrosine
kinases showed a 3-fold higher signal with than without the peptide. Of these, AXL and
EPHB3 were most interesting to me, as they had higher overall activity and both are
receptor tyrosine kinases upstream of signaling pathways including PI3K/AKT and those
regulating cell migration (Weinger et al. 2008; Abu-Thuraia et al. 2020; Lin et al. 2015; Li et
al. 2012). In particular, AXL has been shown to colocalize with F-actin at the leading edge of
human cancer cells and is important for cell migration (Zajac et al. 2020). AXL also has a
connection to p85 proteins, as p85α and p85β have been shown associate with AXL
phosphorylation sites (Braunger et al. 1997; Weinger et al. 2008).
Interestingly, in D. discoideum, where actin Y53 phosphorylation is very prominent, no
dedicated actin Y53 kinase has been identified either. However, a few candidates have
been tested. For example, Liu and colleagues mentioned an observation that Zak1, Zak2
and PkyA kinases are likely not actin kinases, as in knockout strains of these enzymes,
tyrosine phosphorylation is increased upon phosphatase inhibitor treatment (Liu et al. 2006).
Kishi and colleagues mentioned that they had observed a reduction of actin tyrosine
phosphorylation in a strain lacking splA (Kishi et al. 1998). This enzyme is a dual-specificity
kinase with a preference for tyrosine and, while not conserved in mammals, shares a motif
with human Eph family kinases (Nuckolls et al. 1996).

In summary, I have found two interesting kinase candidates that may be involved in
phosphorylating actin at the Y53 residue, and also obtained data showing which kinases are
likely not responsible for applying this modification, such as the EGF and insulin receptors.
However, further confirmation is needed to test whether AXL and or EPHB3 can
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phosphorylate actin in cells under physiological conditions, and how this phosphorylation of
actin is regulated. Aside from mass spectrometry or specific actin pY53 antibodies, another
possibility to test this would be to use an affinity-tagged p85 SH2 domain to try and enrich
for the phosphorylated actin to detect whether there is an increase upon AXL or EPHB3
activation with their respective ligands.
Given that the sequence around the Y53 residue is highly conserved (Kashina 2020),
any kinase that can recognize this motif might also be able to phosphorylate other actin
isoforms. It is also important to note that phosphorylation by any kinase may not occur at all
times but only under certain conditions, such as upon RTK activation. Moreover, if actin is
phosphorylated by an RTK, which are usually membrane-bound, it would indicate that
phosphorylated actin may also be found primarily in close proximity to the plasma
membrane.
Functionally, it is possible that there may be redundancy between different kinases that
phosphorylate actin, depending on the precise subcellular localization, expression and
activation state. Given that we only observed relatively low levels of activity of both AXL and
EPHB3 towards the actin peptide, it is possible that there are other kinases with higher
activities that we have not tested. Humans have less than 100 tyrosine kinases (Manning et
al. 2002), and most of them were included in the assay, yet there are a few tyrosine kinases
we have not ruled out. Moreover, tyrosine residues can also be phosphorylated by dualspecificity kinases that can act as both serine/threonine and tyrosine kinases (Roskoski
2015), which we have not tested. Another possible explanation is that the relatively short
peptide sequence provided in the assay is not sufficient to mediate efficient phosphorylation,
and that higher activity would be achieved with a full-length actin protein.
Lastly, it would be interesting to explore not only kinases, but also protein tyrosine
phosphatase(s) (Alonso et al. 2004) that may remove actin Y53 phosphorylation.
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Conclusions and future perspectives

In summary, I performed an analysis of actin Y53 phosphorylation by identifying p85 and
VAV2 as potential ‘reader’ proteins for this actin PTM. My biochemical and structural
analyses show that the actin pY53 peptide can bind to the N-terminal SH2 domains of p85α
and p85β in a phosphorylation-dependent manner, with a partially unique mechanism of
interaction and an affinity in a similar range of typical SH2 domain-peptide interactions. My
functional analysis of a cell line with a Y53F mutation in β-actin revealed an altered protein
and gene expression profile in both untreated and insulin-treated cells, as well as
differences of important phosphorylation sites on several proteins, suggesting that the
mutation, and, by extension, possibly actin Y53 phosphorylation, may play an important role
in regulating cell signaling and gene expression. While more research is needed to confirm
these findings and provide a more detailed mechanistic explanation to connect them
directly, including through determination of actin pY53 levels and subcellular localization of
both modified actin and the interactions upon growth factor stimulation, my results suggest a
potentially important connection between actin phosphorylation and SH2 domain-containing
proteins. This hints at a possible mechanism in which actin can be phosphorylated by
dedicated kinases to facilitate these interactions and regulate cellular signaling pathways.
This concept presents a departure from the common view of actin as only a structural
protein and the endpoint of signaling pathways, to an active participant through its PTMs.
As actin tyrosine phosphorylation is among the most frequently identified actin PTMs, it
will be important to dissect overlapping and distinct roles of different actin tyrosine
phosphorylation sites. Our screen for ‘readers’ of the most frequently found sites shows that
different actin phosphotyrosine peptides can interact with different SH2 domains or subsets
thereof, which suggests that they may also have distinct functions in signaling by mediating
interactions between actin and a number of SH2 domain-containing proteins. Moreover,
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aside from actin pY53, the impact of other tyrosine phosphorylation sites on actin
polymerization and cytoskeletal structure is largely unknown. It will be critical to determine
the interplay and relative importance of actin PTMs on polymerization and filament dynamics
on one hand, and interactions with ‘reader’ proteins on the other hand.
In the future, I envision that systematic studies of actin PTMs, for example through mass
spectrometry, will yield a more comprehensive insight into the identity, abundance and
context-dependent occurrence of actin PTMs. Recent work from our group showed that
many actin PTMs are highly conserved and exist in yeast as well as humans, and some,
such as R256 methylation, are specific to the cell nucleus (Kumar et al. 2020). Expanding
these systematic studies to mouse and human cells lines, different tissue types, as well as
to clinically relevant samples like tumor tissue, will broaden the horizon of actin PTM studies
and may lead to the discovery of disease mechanisms or even novel therapeutic targets. In
addition to detecting these modifications, continuing to investigate their regulation and
downstream functions on a mechanistic level by defining their ‘readers’, ‘writers’ and
‘erasers’ holds promise to decipher the ‘Actin Code’ and gain functional insight into the roles
of actin PTMs in the cell.
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Chapter IV: MATERIALS AND METHODS
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Reagents

Antibodies
Anti-FLAG (M2) and anti-β-actin (AC-15) antibodies were purchased from Sigma Aldrich.
Pan-actin antibody (Clone C4) was from Millipore. Antibodies for AKT, AKT pS473, HA,
GST, DUSP4, NDRG1 pS346, DVL3, as well as mouse IgG1 and rabbit IgG isotype controls
were from Cell Signaling Technology. Antibodies for p85β were from Abcam. The VAV2
antibody was from Santa Cruz Biotechnologies. Anti-AXL and rabbit anti-goat secondary
antibody were purchased from R&D Systems. The α-tubulin antibody was from
Developmental Studies Hybridoma Bank (DSHB). Secondary antibodies used for western
blot were m-IgGκ-BP-HRP from Santa Cruz Biotechnologies and AffiniPure goat anti-rabbit
IgG from Jackson ImmunoResearch Laboratories, Inc.
Custom polyclonal antibodies were produced by Biomatik. Briefly, two rabbits were
immunized with a phosphorylated peptide around the Y53 residue
(GQKDSpYVGDEAQSKRG-Cys) conjugated to KLH. Antibodies were isolated from rabbit
serum after completion of the immunization protocol and affinity purified with the peptide
antigen.

Peptides
Custom peptides were purchased from CPC Scientific and reconstituted in the
recommended solvent (H2O, PBS or formic acid) to 1 - 25 mg/ml. Peptides used for protein
domain arrays, pull-down assays and the in vitro phosphorylation assay were 17 amino
acids in length with the tyrosine residue of interest in the center, and an N-terminal biotin
tag. The peptide used to generate the final crystal structures was 9 amino acids in length
(KDSpYVGDEA) and had no biotin tag.
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Chemicals and supplies
DynabeadsTM MyOneTM Streptavidin T1, DynabeadsTM Protein G, and Ultra StreptavidinHRP were purchased from ThermoFisher Scientific. Anti-FLAG® M2 magnetic beads were
from Sigma. Glutathione SepharoseTM 4B beads were from GE Healthcare. Wortmannin,
Insulin, IGEPAL® CA-630 and Crystal Violet were purchased from Sigma. All restriction
enzymes used for cloning and PCR fragment digestion were purchased from New England
Biolabs. Kits used for RNA isolation for RNA sequencing (RNeasy Plus, QiaShredder) and
plasmid DNA preparations (QIAprep Spin miniprep kit, Qiagen Plasmid Plus Midi kit) were
purchased from Qiagen. Type I Collagen solution for coating cell culture dishes for migration
assays was purchased from Advanced Biomatrix.

Experimental Methods

Cell culture and transfection
Cell lines were purchased from American Type Culture Collection (ATCC). Human
embryonic kidney (HEK293) (CRL-1573TM) and HeLa (CCL-2) cells were cultured in
Dulbecco’s Modified Eagles Medium (DMEM) (ThermoFisher) supplemented with 10 %
Fetal Bovine Serum (Sigma), unless noted otherwise for specific assays, at 37 °C and 5 %
CO2. Transient transfections were carried out using jetPrime kit (Polyplus Transfection)
according to the manufacturer’s instructions.
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Protein domain arrays
Protein domain arrays were performed by the MD Anderson Protein Array and Analysis
Core (PAAC) under supervision of Dr. Mark Bedford. Briefly, protein domains are spotted on
nitrocellulose slides, followed by blocking of the slides and incubation with biotinylated
peptides that have been labeled with streptavidin. After washing the slides, fluorescence
signal is detected with a microarray scanner. Detection of GST is performed to ensure equal
loading of protein domains.

Western blot
Western blots were performed according to standard protocols. Briefly, protein samples
in SDS and glycerol-containing loading buffer with 5 % DTT were resolved by SDS-PAGE.
Transfer to methanol-activated PVDF membranes was carried out at constant voltage
(100 V) for 45 minutes in Tris-Glycine buffer with 20 % methanol. Efficiency of transfer was
confirmed by staining with 0.1 % Ponceau S (Sigma) for 2 minutes. Membranes were
blocked in 5 % BSA or 5 % skim milk in TBS-T buffer, depending on the primary antibody,
for 1 hour at room temperature before incubating with primary antibody either overnight at
4 °C or for one hour at room temperature. Membranes were then washed in TBS-T and
incubated with secondary antibody for one hour at room temperature, followed by additional
TBS-T washes. Detection was carried out using ECL reagent in an Amersham Imager 600
or on film.

Cloning and PCR
The FLAG-tagged β-actin construct was generated by Dr. Yuan Zhong. Briefly, RNA was
isolated from HEK293 cells using RNeasy Plus kit (Qiagen) and reverse transcribed to
cDNA. The ACTB coding sequence was amplified by PCR using PfuTurbo DNA Polymerase
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(Agilent), and a second round of amplification with primers to add restriction sites for BamHI
and NotI. p3xFLAG-CMVTM-7.1 backbone and the PCR products were digested with BamHIHF (NEB) and NotI-HF (NEB). The backbone was dephosphorylated with CIP (NEB), and
PCR products and backbone were gel purified and ligated with T4 DNA ligase (NEB). The
ligation reaction was transformed in E. coli DH5α and plasmid DNA from single colonies was
isolated. Correct in-frame insertion and integrity of the ACTB coding sequence was
confirmed by Sanger sequencing. To generate the FLAG-β-actin Y53F and Y53A
constructs, as well as to delete C-terminal residues from the pGEX p85α-SH2 and pGEX
p85β-SH2 constructs, mutagenic primers for site directed mutagenesis (SDM) were
designed with PrimerX (http://www.bioinformatics.org/primerx). PCR using these primers
was carried out using PfuTurbo DNA Polymerase (Agilent). PCR products were digested
with DpnI enzyme (NEB) to remove the original template and transformed into E. coli XL10
competent cells (Agilent), followed by Sanger sequencing to confirm presence of the desired
sequence. The VAV2 SH2 domain deletion construct was generated from pC.HA Vav2
backbone using PCR with PfuTurbo DNA Polymerase to amplify the plasmid except for the
SH2 domain, followed by digestion with DpnI enzyme (NEB), re-ligation and transformation
in E. coli XL10 competent cells (Agilent). Deletion of the domain and in-frame re-ligation
were confirmed by Sanger sequencing.
Additional constructs used in this work were gifts from Joan Brugge (pC.HA Vav2
Addgene #14554, pC.HA Addgene #15126) (Moores et al. 2000), Ronald Kahn (pSV human
p85α HA tag Addgene #11499) (Ueki et al. 2003) as well as Leszek Kotula and Bruce Mayer
(pGEX p85α(N)-SH2 Addgene #46464, pGEX p85β(N)-SH2 Addgene #46467, pGEX Vav2SH2 Addgene #46529) (Machida et al. 2007). The pDEST15-PIK3R3_N construct was
generated by Dr. Shawn Li (Department of Biochemistry, University of Western Ontario),
and obtained from Dr. Mark T. Bedford (MD Anderson Cancer Center).

119

SH2 domain expression and purification
Expression vectors were transformed in E. coli BL21, except for p55γ SH2 domain
construct with a pDEST15 backbone, which was transformed in BL21-AI cells, and
inoculated in LB medium with Carbenicillin. For small scale preparations, 5 ml overnight
cultures were diluted in 50 or 100 ml LB-Carb and expression was induced with 0.2 or
0.4 mM IPTG (and 0.2 % arabinose for pDEST15 p55γ-N-SH2 plasmid) at OD600 =
0.6 ~ 0.8. Expression was carried out at 30 °C for 4 hours. Cells were collected by
centrifugation, resuspended in lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 5 % glycerol,
0.5 mM DTT, 0.1 mM PMSF), sonicated (30 % amplitude, 2 x 20 s), and centrifuged again at
full speed. Supernatant was incubated with 100 µl Glutathione Sepharose beads overnight
with end-over-end rotation, 20 rpm at 4 °C.
Large scale protein expression for ITC and crystallography was performed essentially
the same, but in a larger volume. Induction with IPTG was carried out in 3 x 2-liter cultures
for 4 hours at 30 °C. Cells were collected by centrifugation and stored frozen at -80 °C until
further use. Cell pellets were thawed, resuspended in lysis buffer (50 mM Tris, pH 7.5,
150 mM NaCl, 5 % glycerol, 0.5 mM TCEP, 0.1 mM PMSF) and sonicated at 60 %
amplitude 4 x 60 s with 10 s on, 30 s off, followed by centrifugation (23,000 g, 40 min).
Supernatant was added to an equilibrated Glutathione Sepharose column. The column was
washed with 150 ml buffer and bound proteins were eluted with 50 ml elution buffer
(20 mM Tris pH 8.0, 150 mM NaCl, 5 % glycerol, 0.5 mM TCEP, 20 mM Glutathione). Eluted
proteins were then mixed with ~ 100 µg PreScission (for pGEX-6P-1 expression vector) or
Thrombin (for pGEX-4T-1 expression vector) protease overnight at 4 °C to remove the GST
tag. SH2 domains were further purified by Fast Protein Liquid Chromatography (FPLC) with
an anion exchange column (HiTrap Q; linear gradient of Buffer A (20 mM Tris pH 8.0, 5 %
glycerol, 0.5 mM TCEP) to Buffer B (20 mM Tris pH 8.0, 1 M NaCl, 5 % glycerol, 0.5 mM
TCEP)) followed by protein concentration (Millipore Ultra Amicon 3 kDa) and loading of the
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protein on a sizing column (HiLoad 16/60 Superdex 75 PG; Buffer: 20 mM Tris pH 8.0,
150 mM NaCl, 5 % glycerol, 0.5 mM TCEP). Purified protein domains were then used for
ITC and crystallography. Large-scale protein purification was performed by Dr. Shaobo Dai.

Peptide pull-down
Peptide pull-downs were carried out in PPD buffer (50 mM Tris-HCl, pH 8.0, 150 mM
NaCl and 0.1 % IGEPAL). Streptavidin beads were washed twice with PPD buffer followed
by incubation with 12 µg of biotinylated peptide for one hour, end-over-end rotation at
20 rpm, 4 °C in PPD buffer. After three washes with PPD buffer to remove unbound peptide,
purified GST-tagged SH2 domains (~ 1 µg) were added and incubated overnight at endover-end rotation at 20 rpm, 4 °C in PPD buffer with the peptide coupled beads. Beads with
no peptide bound were used as a control. After incubation, four additional washes with PPD
buffer were performed and bound protein was eluted into SDS-PAGE loading buffer with
5 % DTT by boiling for 5 minutes. Proteins and peptides were then resolved by SDS-PAGE,
transferred, and western blots were probed with GST antibody and Streptavidin-HRP.
Peptide pull-downs from cell lysate were carried out in a similar manner, except that whole
cell lysate (in buffer containing 50 mM HEPES pH 7.5, 150 mM NaCl, 1.5 mM MgCl2, 1 mM
EGTA, 10 % glycerol, 1 % Triton X-100, 1 mM sodium orthovanadate, 10 mM NaF, 10 mM
sodium pyrophosphate, and 1x protease inhibitors) from HEK293 cells (untransfected or
transfected with HA-tagged p85α) was added to the peptide-coupled beads instead of
purified SH2 domains, and pull-down was carried out with lysis buffer instead of PPD buffer.

Isothermal Titration Calorimetry
ITC measurements were carried out using a Malvern MicroCal PEAQ-ITC Automated
system by Dr. Shaobo Dai (Dr. Xiaodong Cheng’s laboratory). Peptides were dissolved in
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H2O to a 10 mM stock solution and used at 400 µM (syringe concentration) for ITC
measurements. Protein concentration (measurement cell) was 40 µM. ITC buffer was
20 mM Tris pH 8.0, 50 mM NaCl, 5 % glycerol, 0.5 mM TCEP. Measurements were
performed with a preliminary injection of 0.2 µl followed by 18 injections of 2 µl each over the
course of 96 minutes. Data analysis was carried out with the instrument manufacturer’s
software using a one-set-of-sites model.

Crystallization and acquisition of structural data
An Art Robbins Phoenix Crystallization Robot was used to set up 0.4 μl sitting drops at
~ 20 °C of the binary complexes of purified SH2 domains (15 mg/ml, 1 mM) with pY53
peptide (3 mM) as well as the well solutions. For the p85α N-SH2 domain, the well solution
that yielded crystals was 0.05 M cadmium sulfate hydrate, 0.1 M HEPES, pH 7.5 and 1.0 M
sodium acetate trihydrate. For the p85β N-SH2 domain crystals, the well solution was
25 % (w/v) PEG 1500, 100 mM MIB buffer, pH 5.0. For the VAV2 SH2 domain crystals, the
well solution was 0.2 M sodium acetate trihydrate, 0.1 M TRIS hydrochloride, pH 8.5, 30 %
polyethylene glycol 4000. Crystals were flash frozen using 20 % (v/v) ethylene glycol for
cryo-protection.
For the p85β SH2 domain, X-ray diffraction data were collected at SER-CAT 22-ID
beamline of the Advanced Photon Source (Argonne National Laboratory) and processed by
HKL2000; for p85α and VAV2 SH2 domains, X-ray diffraction data were collected at an inhouse (Dr. Xiaodong Cheng laboratory, MD Anderson Cancer Center) Rigaku facility
equipped with a MicroMax-003 Microfocus sealed tube X-ray generator, an AFC11 partial-χ,
4-axis goniometer and an HyPix-6000HE hybrid photon counting detector. The datasets
collected from the in-house source were processed with CrysAlisPro (Rigaku) and were
scaled and merged with the AIMLESS program of the CCP4 interface. Molecular
replacement was performed with PHENIX PHASER module using the structure of the PI3K
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p85 N-terminal SH2 domain in complex with PDGFR phosphotyrosyl peptide (PDB ID 2IUI)
(Nolte et al. 1996) as the search model. Structure refinement was performed with Phenix
Refine with 5 % randomly chosen reflections for validation by Rfree value. COOT was used
for the manual building of a structure model and corrections between refinement rounds.
Structure quality was analyzed during PHENIX refinements. Molecular graphics were
generated using PyMol Molecular Graphics Software (Schrödinger, LLC). All abovementioned steps, including preparation of data collection and refinement tables and
methods description were carried out by Dr. Shaobo Dai (Xiaodong Cheng Laboratory, MD
Anderson Cancer Center), except for the preparation of molecular graphics.

Co-immunoprecipitation
HEK293 or HeLa cells were seeded in 10 cm dishes and transfected with p3xFLAGCMVTM-7.1-ACTB WT, ACTB Y53F or ACTB Y53A plasmids or empty vector, as indicated in
the figure legends. After 24 hours, 1 mM sodium orthovanadate was added to the cells for
30 minutes. Then, cells were washed with PBS, collected in lysis buffer (25 mM HEPES
pH 7.5, 150 mM NaCl, 0.5 % IGEPAL, 5 % glycerol, supplemented with protease inhibitors
and sodium orthovanadate), rotated at 4 °C for 20 minutes and centrifuged (16,300 g,
10 minutes, 4 °C). Supernatant protein concentration was quantified with Bradford assay.
Anti-FLAG® magnetic beads were added to the supernatants and incubated overnight or 4
hours with rotation at 4 °C followed by washes with lysis buffer. For endogenous IP or other
protein tags, cell lysates were incubated overnight with the respective antibody followed by
adding Protein G Dynabeads for 1 hour and subsequent washes. After IP, bound proteins
were eluted by boiling the beads for 5 minutes in SDS-PAGE loading buffer containing 5 %
DTT. Proteins were resolved by SDS-PAGE followed by western blotting.
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Generation of β-actin Y53F mutation in HeLa cells
Prime editing to create an ACTB Y53F mutation was performed in HeLa cells essentially
as described in Anzalone et al., 2019 using the PE3 system. Plasmids used for prime editing
were gifts from David Liu (Addgene #132777 and #132777) (Anzalone et al. 2019) and Keith
Joung (Addgene #65777) (Kleinstiver et al. 2015). Guide RNA sequences and extensions
were selected using the www.benchling.com website, and assembled to yield pegRNA and
sgRNA sequences with the required overhangs for cloning (Table 5). Three pegRNAs and
three sgRNAs with the best on-target and off-target scores were selected. pegRNA, sgRNA
and PE2 plasmids were co-transfected into HeLa cells using jetPrime kit according to the
manufacturer’s instructions. Four days after transfection, cells were detached and diluted to
yield approximately one cell per well in a 96-well plate, and cell growth was monitored daily.
Wells containing more than one cell or colony were excluded and cell clones were expanded
into 24-well plates. Genomic DNA was isolated using standard ethanol precipitation
protocols. PCR of the ACTB locus was performed followed by digestion of the PCR product
with HpyAV enzyme (NEB) to distinguish mutated and unaltered alleles as well as detect
potential indels. Successful editing was confirmed by Sanger sequencing.

Insulin stimulation assay
HeLa parental and β-actin Y53F cells were seeded in 6-well plates. On the next day,
culture medium was replaced with serum-free medium. After 18 hours, cells were either pretreated with 500 nM Wortmannin for 15 min followed by treatment with 250 nM insulin for
15 min, insulin only, or no treatment. Cells were washed once with ice-cold PBS and
collected in lysis buffer (25 mM HEPES pH 7.5, 150 mM NaCl, 0.5 % IGEPAL, 5 % glycerol,
supplemented with protease and phosphatase inhibitors). Lysates were prepared as
described above followed by western blotting and probing with respective antibodies.
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Reverse Phase Protein Array (RPPA)
HeLa parental and β-actin Y53F cells were seeded in 10 cm plates (one plate for each
technical replicate). On the next day, culture medium was replaced with serum-free medium.
After 18 hours, cells were treated with 250 nM insulin for 15 min or no treatment. Cells were
washed once with PBS, collected by scraping, washed twice with PBS, and cell pellets were
stored at -80 °C. RPPA was performed by MD Anderson’s Functional Proteomics Core
Facility (Director: Yiling Lu, MD). Briefly, cells were lysed by the RPPA core and five 2-fold
serial dilutions of the lysates were arrayed on nitrocellulose slides. The lysate spots were
then probed with the respective antibodies (485 unique antibodies in total) using tyramidebased signal amplification and visualized with colorimetric DAB (3,3’-Diaminobenzidine)
reaction, followed by scanning on a Huron TissueScope. From the generated images,
density of sample spots was quantified by Array-Pro Analyzer 6.3 and relative protein levels
were extrapolated from the densities of the serial dilution sample spots. Relative protein
levels were normalized for protein loading. Statistical analysis of the results was carried out
by Dr. Daniel McGrail (MD Anderson Cancer Center) using rank-sum tests with BenjaminiHochberg false discovery rates for direct comparisons (untreated only, insulin-treated only,
analysis of insulin treatment changing differences) or a linear regression model (changes
independent of treatment). Volcano plots were created using the VolcanoNoseR web app
(https://huygens.science.uva.nl/VolcaNoseR2/) (Goedhart and Luijsterburg 2020).

RNA sequencing
HeLa parental and β-actin Y53F cells were seeded in 6-well plates in three technical
replicates per treatment condition. On the next day, complete culture medium was replaced
with serum-free medium and cells were incubated for 18 hours followed by no treatment or
treatment with 250 nM insulin for 2 and 6 hours. Cells were washed once with PBS and
RNA was isolated using the Qiagen RNeasy Plus mini kit (Qiagen) according to the
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manufacturer’s instructions. Library preparation and RNA sequencing was carried out by the
MD Anderson Science Park Next Generation Sequencing Core facility (Director: Dr. Jianjun
Shen). RNA quality was measured with Bioanalyzer RNA Nano Assay and yielded an RNA
integrity number (RIN) of ~ 10 for all samples. Purification of mRNA, cDNA synthesis, 3’ end
adenylation, adapter ligation, PCR amplification and library normalization were carried out
with a TruSeq Stranded mRNA-seq sample preparation kit according to the manufacturer’s
instructions by the core facility. Sequencing of the libraries was performed on an Illumina
HiSeq 3000 instrument (paired-end reads, 75 cycles). Bioinformatics analysis of the raw
sequencing data was performed by Dr. Bin Liu (MD Anderson Science Park Bioinformatics
Core): Briefly, the raw RNA sequencing readouts were mapped to the human assembly
reference genome (GRCh38) using TopHat2 (Kim, Pertea, et al. 2013), an open-source
software tool that aligns RNA sequencing reads to a reference genome. Differential gene
expression analysis was performed with DESeq2 (R/Bioconductor package) (Love, Huber,
and Anders 2014) using adjusted p-value of < 0.05 as the significance cutoff.
Area-proportional Venn diagrams were generated using the BioVenn web tool
(https://www.biovenn.nl/) (Hulsen, de Vlieg, and Alkema 2008).

Proliferation assay
Cells were seeded in 12-well plates with four wells per day for each cell line or condition
and one plate for each day. Proliferation was measured every 24 hours for four days using
crystal violet staining. Briefly, cells were washed once with PBS, 500 µl crystal violet solution
was added to each well and incubated with gentle shaking for 20 minutes. Afterwards, three
washes with water were performed to remove excess staining solution and plates were dried
for at least one day. Then, 500 µl methanol were added per well and incubated for
10 minutes with gentle shaking. 250 µl were transferred to a 96-well plate and absorbance
was measured at 595 nm using a FLUOStar Omega plate reader (BMG Labtech). Data were
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analyzed in GraphPad PRISM using a two-way ANOVA with Geisser-Greenhouse
correction.

Migration assay
6-well plates were coated with collagen (Advanced Biomatrix) and 4-well inserts (Ibidi)
were placed in the wells. Cells were seeded according to manufacturer’s instructions. After
removing the inserts, cells were cultured in serum-free medium supplemented with or
without 250 nM insulin (Sigma) and cell migration was monitored by taking images of the
gaps at 0, 24 and 48 hours with a Nikon Eclipse TS100 microscope and Photometrics
CoolSNAPTM camera, using the manufacturer’s software package (NIS-Elements AR 3.10).
Migration was analyzed using the ImageJ software (Schneider, Rasband, and Eliceiri 2012)
by manually measuring the size of remaining cell-free area in each image. Data were
analyzed in GraphPad PRISM using two-way ANOVA, separately for untreated and insulintreated samples.

Peptide dot blot
Serial dilutions of peptides were spotted on nitrocellulose membranes. Membranes were
dried for one hour and blocked with 5 % BSA in TBS-T for one hour followed by incubation
with primary antibody or Streptavidin-HRP. After washing with TBS-T, membranes were
incubated with secondary antibody and detected with ECL reagent in an Amersham 600
imager.

In vitro phosphorylation assay
The in vitro phosphorylation assay of an actin Y53 peptide (biotinylated 17 amino acid
peptide, CPC Scientific) was performed by Reaction Biology Europe GmbH (Freiburg,
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Germany). Briefly, according to the company’s assay description, a panel of 94 different
tyrosine kinases was tested using the radiometric 33PanQinase® assay. For the assay,
reaction cocktails containing the kinase solution (1 - 400 ng/50 µl) and buffer (60 mM
HEPES, pH 7.5, 3 mM MgCl2, 3 µM sodium orthovanadate, 1.2 mM DTT, 1 µM ATP/[γ-33P]ATP (7.0 x 1005 cpm/well) and the peptide (1 µM) were incubated for 60 minutes, the
reaction stopped by addition EDTA and then transferred to streptavidin-coated plates,
incubated, washed and radioactive 33Pi was measured using a microplate scintillation
counter (Perkin Elmer). The background signal for each kinase as well as the streptavidincoated plates was determined in parallel and subtracted from the resulting kinase activity
values.

Data analysis and statistics
Statistical analysis for RNA sequencing and RPPA was carried out as indicated in the
methods description for the respective method. All other statistical analysis was carried out
in GraphPad Prism 8 using two-way ANOVA as indicated. Statistical significance was
defined as a p-value of < 0.05, except where otherwise indicated in the figure legend.
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Table 5. Sequence of prime editing guideRNAs and pegRNA scaffold.
Component

Sequence (5’ – 3’) with overhangs for cloning

Spacer 1 (top)

CACCGGGTCAGAAGGATTCCTATGGTTTT

Spacer 1 (bottom)

CTCTAAAACCATAGGAATCCTTCTGACCC

Spacer 2 (top)

CACCGATGGTGGGCATGGGTCAGAGTTTT

Spacer 2 (bottom)

CTCTAAAACTCTGACCCATGCCCACCATC

Spacer 3 (top)

CTCTAAAACATGTGGGCGACGAGGCCCAGAGC

Spacer 3 (bottom)

CACCGCTCTGGGCCTCGTCGCCCACATGTTTT

Extension 1 (top)

AAAACAGAAGGATTCCTTCGTGGGCGACGAGG

Extension 1 (bottom)

GTGCCCTCGTCGCCCACGAAGGAATCCTTCTG

Extension 2 (top)

AAAAGTGGGCATGGGTCAGAAGGATTCCTTCGTGGGC

Extension 2 (bottom)

GTGCGCCCACGAAGGAATCCTTCTGACCCATGCCCAC

Extension 3 (top)

GTGCGGGTCAGAAGGATTCCTTCGTGGGCGACGAGGC

Extension 3 (bottom)

AAAAGCCTCGTCGCCCACGAAGGAATCCTTCTGACCC

pegRNA scaffold (top)
pegRNA scaffold (bottom)

AGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGT
CCGTTATCAACTTGAAAAAGTGGCACCGAGTCG
GCACCGACTCGGTGCCACTTTTTCAAGTTGATA
ACGGACTAGCCTTATTTTAACTTGCTATTTCTAG

PE3 sgRNA 1 (top)

AAACCATCGAGCACGGCATCGTCA

PE3 sgRNA 1 (bottom)

CACCTGACGATGCCGTGCTCGATG

PE3 sgRNA 2 (top)

AAACGAAGTACCCCATCGAGCACG

PE3 sgRNA 2 (bottom)

CACCCGTGCTCGATGGGGTACTTC

PE3 sgRNA 3 (top)

CACCGGGGGCTGCGCCCGTGCTCA

PE3 sgRNA 3 (bottom)

AAACTGAGCACGGGCGCAGCCCCC

Sequences used to construct the cell line used in the functional studies are highlighted in
bold.
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Table 6. Thermodynamic parameters of ITC experiments with short actin pY53 peptide
without adjusting stoichiometry.
Protein

p85α N-SH2

p85β N-SH2

VAV2 SH2

KD (µM)

6.3 ± 2.3

1.4 ± 0.3

2.4 ± 0.7

Na

1.2 ± 0.1

1.22 ± 0.03

1.26 ± 0.06

ΔG (kcal/mol)

-7.10

-8.01

-7.68

ΔH (kcal/mol)

-6.28

-5.44

-5.88

-TΔS (kcal/mol)

-0.818

-2.56

-1.80

Peptide: KDSpYVGDEA
a
Table contains data from the same ITC measurements as Table 1, but without adjusting the
stoichiometry of the interaction to N = 1.

Table 7. Thermodynamic parameters of ITC experiments with longer actin pY53
peptide.
Protein

p85α N-SH2

p85β N-SH2

VAV2 SH2

KD (µM)

4.6 ± 0.6

2.2 ± 0.5

3.7 ± 0.6

N

0.99 ± 0.02

0.97 ± 0.03

1.04 ± 0.02

ΔG (kcal/mol)

-7.28

-7.71

-7.41

ΔH (kcal/mol)

-6.50

-7.38

-8.62

-TΔS (kcal/mol)

-0.781

-0.336

1.22

Peptide: Biotin-VGMGQKDSpYVGDEAQSK
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Figure 25. SH2 protein domain array results for additional actin pY peptides. The SH2
domain array was probed with 100 µg of biotinylated phosphotyrosine peptides (17 amino
acids), around residues Y53 (A), Y91 (B), Y198 (C) and Y294 (D) (gain 0.01). GST was
detected to serve as a loading control (gain 0.07) (E). Only the pY53 peptide binds
selectively to the N-SH2 domains of p85β, p85β, p55γ, and VAV2. Weak binding to these
domains is also detected for the pY294 peptide, but this peptide binds more strongly to SH2
domains of ABL1, ABL2, GRAP and GADS/GRAP2. Both the pY91 and the pY198 peptides
bind to the SH2 domain of CRK, but binding is stronger for pY91. Data were generated by
Cari Sagum (PAAC, MD Anderson Cancer Center).
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Figure 26. Comparison of all three SH2 domains bound to the actin pY53 peptide. (A)
Overlay of p85α (gray) and p85β (green; chains E, F) N-SH2 domains bound to actin pY53
peptide. (B) Surface view of the p85α N-SH2 domain bound to actin pY53 peptide. (C)
Surface view of the p85β N-SH2 domain bound to actin pY53 peptide. (D) Surface view of
the VAV2 SH2 domain bound to the actin pY53 peptide. Crystal structures were generated
by Dr. Shaobo Dai (Dr. Xiaodong Cheng laboratory, MD Anderson Cancer Center).
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Figure 27. Comparison of differentially expressed proteins and PTMs in RPPA.
Volcano plots of direct comparisons between Y53F mutant and parental cells for untreated
cells only (A) or insulin-treated cells only (B). Higher levels in the mutant cells are on the
right side of the graph in red, and lower levels on the left side in blue. Horizontal dotted line
denotes a p-value of 0.05 (rank-sum test). RPPA data were generated by the Functional
Proteomics Core Facility (MD Anderson Cancer Center).
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Figure 28. Distribution of differentially expressed genes in Y53F mutant versus
parental cells. (A) Differentially expressed genes in Y53F mutant vs. parental after 6 hours
of insulin treatment. Upregulated genes (red) and downregulated genes (blue) in the Y53F
vs. parental with a Log2 fold change cut-off of ± 1.0. (B) Differentially expressed genes in
Y53F mutant vs. parental after 2 hours of insulin treatment. Upregulated genes (red) and
downregulated genes (blue) in the Y53F vs. parental with a Log2 fold change cut-off of ± 1.0.
(C) Differentially expressed genes in parental cells at 6 hours of insulin treatment vs.
untreated. Upregulated genes (red) and downregulated genes (blue) with a Log2 fold change
cut-off of ± 1.0. (D) Differentially expressed genes in Y53F mutant cells at 6 hours of insulin
treatment vs. untreated. Upregulated genes (red) and downregulated genes (blue) with a
Log2 fold change cut-off of ± 1.0. Diagrams in this figure were generated by Dr. Bin Liu (MD
Anderson Cancer Center).
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